CHIR-99021 (CT99021) HCl

Name: CHIR-99021 (CT99021) HCl
Brand: Selleck Chemicals
SKU: S2924
Rating: 5 (207 reviews)

For research use only.

Catalog No.S2924

207 publications

CHIR-99021 (CT99021) HCl Chemical Structure

CAS No. 1797989-42-4

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.

Selleck's CHIR-99021 (CT99021) HCl has been cited by 207 publications

Nature, 2020,

PubMed: 32814902 ( click the link to review the publication )

Cell, 2020, 30;181(3):621-636

PubMed: 32259487 ( click the link to review the publication )

Cell Stem Cell, 2020, S1934-5909(20)30447-1

PubMed: 32991838 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cell Stem Cell, 2019, 24(5):802-811

PubMed: 30880024 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Cell, 2018, 174(2):391-405

PubMed: 29937225 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):462-477

PubMed: 28111200 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(5):720-731

PubMed: 28343982 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):518-532

PubMed: 28017796 ( click the link to review the publication )

Nature, 2016, 17;539(7629):452-455.

PubMed: 27783602 ( click the link to review the publication )

Nature, 2015, 13;524(7564):234-8.

PubMed: 26176921 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Cell Stem Cell, 2015, 10.1016/j.stem.2015.04.020

PubMed: ( click the link to review the publication )

Nat Biotechnol, 2014, 32(11):1121-33

PubMed: 25211370 ( click the link to review the publication )

Nature, 2013, 8;500(7461):222-6.

PubMed: 23812591 ( click the link to review the publication )

Cell, 2013, 26;155(1):135-47.

PubMed: 24074866 ( click the link to review the publication )

Cell Res, 2020, 1-18

PubMed: 32913304 ( click the link to review the publication )

Cell Res, 2020, 30(1):21-33

PubMed: 31729468 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2585

PubMed: 32444791 ( click the link to review the publication )

Sci Adv, 2020, 6(24):eaba0777

PubMed: 32704541 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa067

PubMed: 32016422 ( click the link to review the publication )

EMBO J, 2020, 15;39(8):e102961

PubMed: 32090361 ( click the link to review the publication )
Dev Cell, 2020, 6;53(1):42-59

PubMed: 32109383 ( click the link to review the publication )

Biomaterials, 2020, 248:120013

PubMed: 32278152 ( click the link to review the publication )

Biomaterials, 2020, 249:120015

PubMed: 32311594 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 17;30(11):3917-3931

PubMed: 32187559 ( click the link to review the publication )

Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Death Differ, 2020, 1

PubMed: 32483381 ( click the link to review the publication )

Protein Cell, 2020, 10.1007/s13238-020-00713-x

PubMed: 32277346 ( click the link to review the publication )

Mol Ther, 2020, 28(9):2044-2055

PubMed: 32892813 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Stem Cell Reports, 2020, 15(3):646-661

PubMed: 32822589 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cardiovasc Res, 2020, 29 pii: cvaa017

PubMed: 31995179 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 15;39(1):64

PubMed: 32293507 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2020, 6;19:1299-1308

PubMed: 32160702 ( click the link to review the publication )

Cells, 2020, 5;9(6):E1406

PubMed: 32516938 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000206R

PubMed: 32888237 ( click the link to review the publication )

J Mol Cell Biol, 2020, 30 pii: mjaa010

PubMed: 32232340 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):431

PubMed: 33008480 ( click the link to review the publication )

ACS Infect Dis, 2020, 21

PubMed: 32329611 ( click the link to review the publication )

Sci Total Environ, 2020, 6;725:138433

PubMed: 32302844 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

FEBS J, 2020, 287(1):122-144

PubMed: 31569299 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44727

PubMed: 32471864 ( click the link to review the publication )
Environ Pollut, 2020, 261:114153

PubMed: 32088431 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15433

PubMed: 32468734 ( click the link to review the publication )

Int J Mol Sci, 2020, 22;21(8)

PubMed: 32331350 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):209

PubMed: 31937807 ( click the link to review the publication )

J Biol Chem, 2020, 15

PubMed: 32295843 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

J Pharmacol Exp Ther, 2020, 373(3):429-437

PubMed: 32217769 ( click the link to review the publication )

J Biomed Sci, 2020, 27(1):92

PubMed: 32887585 ( click the link to review the publication )

J Biomed Mater Res A, 2020, 108(3):496-514

PubMed: 31707752 ( click the link to review the publication )

Sci China Life Sci, 2020, 63(1):1-17

PubMed: 31564034 ( click the link to review the publication )

Circ J, 2020, 10.1253/circj.CJ-20-0881

PubMed: 32981925 ( click the link to review the publication )

Brain Sci, 2020, 3;10(6):E344

PubMed: 32503260 ( click the link to review the publication )

PLoS One, 2020, 3;15(4):e0230966

PubMed: 32243463 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11828

PubMed: 32678240 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):642

PubMed: 32811806 ( click the link to review the publication )

Elife, 2020, 9:e56008

PubMed: 32644042 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):347

PubMed: 32771055 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11274

PubMed: 32647145 ( click the link to review the publication )

Cell Physiol Biochem, 2020, 54(4):696-706

PubMed: 32706220 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0452-0

PubMed: 32555510 ( click the link to review the publication )

Nature, 2020, 10.1038/s41586-020-2631-z

PubMed: 32814902 ( click the link to review the publication )

EBioMedicine, 2020, 53:102695

PubMed: 32143182 ( click the link to review the publication )

Stem Cells Dev, 2020, 10.1089/scd.2020.0025

PubMed: 32693734 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(14):7856-7863

PubMed: 32619224 ( click the link to review the publication )
Front Cell Dev Biol, 2020, 8:482

PubMed: 32695777 ( click the link to review the publication )

Cytometry A, 2020, 97(4):363-377

PubMed: 31774248 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0621-y

PubMed: 32778844 ( click the link to review the publication )

Stem Cells Dev, 2020, 10.1089/scd.2019.0299

PubMed: 32723003 ( click the link to review the publication )

J Transl Med, 2020, 18(1):283

PubMed: 32664970 ( click the link to review the publication )

Neurobiol Dis, 2020, 105042

PubMed: 32798729 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 1;S2352-345X(20)30088-6

PubMed: 32497793 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30291-5

PubMed: 32795420 ( click the link to review the publication )

Methods Mol Biol, 2020, 10.1007/7651_2020_300

PubMed: 32671814 ( click the link to review the publication )

Nat Genet, 2020, 10.1038/s41588-020-0677-3

PubMed: 32778823 ( click the link to review the publication )

Cell Host Microbe, 2020, 27(1):41-53

PubMed: 31862381 ( click the link to review the publication )

EMBO Rep, 2020, e49863

PubMed: 32783360 ( click the link to review the publication )

Metabolites, 2020, 10(8):E302

PubMed: 32717953 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):100

PubMed: 32127035 ( click the link to review the publication )

J Hazard Mater, 2020, 401:123341

PubMed: 32653787 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(9):1152-1163

PubMed: 31481791 ( click the link to review the publication )

Blood, 2019, blood.2019001037

PubMed: 31570489 ( click the link to review the publication )

Nat Commun, 2019, 10(1):928

PubMed: 30804331 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2939

PubMed: 31270324 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3477

PubMed: 31375664 ( click the link to review the publication )

Sci Adv, 2019, 5(11):eaax7525

PubMed: 31807705 ( click the link to review the publication )

Dev Cell, 2019, 50(2):212-228.e6

PubMed: 31178404 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )

Cell Rep, 2019, 26(13):3643-3656

PubMed: 30917318 ( click the link to review the publication )
Cell Rep, 2019,

PubMed: 31825849 ( click the link to review the publication )

Cell Rep, 2019, 29(8):2461-2472

PubMed: 31747613 ( click the link to review the publication )

Int J Cancer, 2019, 144(2):389-401

PubMed: 29978469 ( click the link to review the publication )

Oncogene, 2019, 38(15):2788-2799

PubMed: 30542117 ( click the link to review the publication )

Stem Cell Reports, 2019, 13(3):485-498

PubMed: 31402336 ( click the link to review the publication )

Mol Metab, 2019, 24:80-97

PubMed: 30930126 ( click the link to review the publication )

PLoS Pathog, 2019, 15(3):e1007667

PubMed: 30901352 ( click the link to review the publication )

FASEB J, 2019, 33(2):2694-2706

PubMed: 30307767 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0605

PubMed: 31395667 ( click the link to review the publication )

Front Neurosci, 2019, 13:867

PubMed: 31551670 ( click the link to review the publication )

Front Physiol, 2019, 10:818

PubMed: 31316396 ( click the link to review the publication )

Cell Cycle, 2019, 18(19):2495-2508

PubMed: 31411525 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):5440-5452

PubMed: 31059099 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Gastroenterology, 2018, 155(5):1508-1523.e10

PubMed: 30055169 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5230

PubMed: 30531796 ( click the link to review the publication )

Sci Adv, 2018, 4(5):eaat0351

PubMed: 29795786 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(47):E11071-E11080

PubMed: 30381455 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Cell Rep, 2018, 25(7):1966-1981.e4

PubMed: 30428361 ( click the link to review the publication )

Cell Rep, 2018, 25(9):2563-2576

PubMed: 30485820 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Stem Cell Reports, 2018, 11(2):497-513

PubMed: 30033084 ( click the link to review the publication )
J Exp Clin Cancer Res, 2018, 37(1):22

PubMed: 29426364 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):598

PubMed: 29789524 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(9):1095-1106

PubMed: 30251630 ( click the link to review the publication )

Dig Dis Sci, 2018, 63(10):2604-2616

PubMed: 29948558 ( click the link to review the publication )

Biol Open, 2018, 7(9)

PubMed: 30135081 ( click the link to review the publication )

Methods Mol Biol, 2018, 1649:473-488

PubMed: 29130217 ( click the link to review the publication )

Curr Protoc Hum Genet, 2018, 10.1002/cphg.64

PubMed: 29979824 ( click the link to review the publication )

Methods Mol Biol, 2018, 1733:127-136

PubMed: 29435928 ( click the link to review the publication )

Cell Res, 2017, 27(6):815-829

PubMed: 28429771 ( click the link to review the publication )

Mol Cell, 2017, 66(4):568-576

PubMed: 28483418 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(31):25929-25940

PubMed: 28718622 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3107

PubMed: 29022923 ( click the link to review the publication )

Biomater Sci, 2017, 5(8):1567-1578

PubMed: 28715029 ( click the link to review the publication )

Stem Cells, 2017,

PubMed: 28090751 ( click the link to review the publication )

Stem Cell Res Ther, 2017, 8(1):156

PubMed: 28676082 ( click the link to review the publication )

Sci Rep, 2017, 7(1):9490

PubMed: 28842634 ( click the link to review the publication )

Biofabrication, 2017, 9(2):025007

PubMed: 28287080 ( click the link to review the publication )

JCI Insight, 2017, 2(18)

PubMed: 28931764 ( click the link to review the publication )

Stem Cells, 2016, 34(7):1765-75

PubMed: 26946228 ( click the link to review the publication )

Sci Rep, 2016, 6:23817

PubMed: 27026509 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0161508

PubMed: 27560518 ( click the link to review the publication )

Exp Ther Med, 2016, 12(6):3851-3858

PubMed: 28101169 ( click the link to review the publication )

Methods Mol Biol, 2016, 1353:181-90

PubMed: 25523811 ( click the link to review the publication )

Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )
Stem Cell Reports, 2016, 7(5):884-896

PubMed: 27720906 ( click the link to review the publication )

Nat Commun, 2015, 6:7413

PubMed: 26172574 ( click the link to review the publication )

Dev Cell, 2015, 32(6):667-77

PubMed: 25805134 ( click the link to review the publication )

Stem Cell Res, 2015, 10.1016/j.scr.2015.05.004

PubMed: ( click the link to review the publication )

Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z

PubMed: 25663198 ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Stem Cells Dev, 2015, 10.1089/scd.2014.0422

PubMed: 25751301 ( click the link to review the publication )

Cell Transplant, 2015, 10.3727/096368914X685762

PubMed: 25562386 ( click the link to review the publication )

Biol Open, 2015, 4(1):48-61

PubMed: ( click the link to review the publication )

J Physiol, 2015, 593(5):1147-57

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144572

PubMed: 26695765 ( click the link to review the publication )

Sci Rep, 2015, 5:9718

PubMed: 25864432 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(6):1128-1142

PubMed: 26626177 ( click the link to review the publication )

Methods Mol Biol, 2015, 10.1007/7651_2015_220

PubMed: 25762297 ( click the link to review the publication )

Methods Mol Biol, 2015, 1264:453-63

PubMed: 25631034 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

Circ Res, 2014, 115(6):556-66

PubMed: 25015077 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(12):4484-9

PubMed: 24623855 ( click the link to review the publication )

Biomaterials, 2014, 35(5):1367-77

PubMed: 24268663 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(4):594-605

PubMed: 25358788 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )
Acta Biomater, 2014, 10(2):604-12

PubMed: 24200714 ( click the link to review the publication )

Protein Cell, 2014, 5(1):59-68

PubMed: 24474197 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):812-22

PubMed: 24552772 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(4):990-1007

PubMed: 24482122 ( click the link to review the publication )

J Biol Chem, 2014, 289(47):32628-38

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14341-50

PubMed: 24692544 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):724-735

PubMed: ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Stem Cells Dev, 2014, 10.1089/scd.2014.0011

PubMed: 24805295 ( click the link to review the publication )

Exp Cell Res, 2014, 328(2):351-60

PubMed: 25172557 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

Exp Biol Med, 2014, 239(10):1390-402

PubMed: 24951472 ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Cell Reprogram, 2014, 10.1089/cell.2014.0028

PubMed: 25084370 ( click the link to review the publication )

J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):151-6

PubMed: 24710923 ( click the link to review the publication )

University of GOTHENBURG, 2014, 5495

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:6425

PubMed: 25236849 ( click the link to review the publication )

Methods Mol Biol, 2014, 10.1007/7651_2014_172

PubMed: 25520292 ( click the link to review the publication )

Nat Commun, 2013, 4:2628

PubMed: 24165455 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )
Stem Cell Res, 2013, 12(2):364-375

PubMed: 24365601 ( click the link to review the publication )

Stem Cell Rep, 2013, 1(4):360-10

PubMed: 24319670 ( click the link to review the publication )

Antioxid Redox Sign, 2013, 20(18):2907-22

PubMed: 24219064 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(8):4102-16

PubMed: 23628704 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35500-10

PubMed: 24165128 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1329-40

PubMed: 23867056 ( click the link to review the publication )

Nat Protoc, 2012, 8(1):162-75

PubMed: 23257984 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(27):E1848-57

PubMed: 22645348 ( click the link to review the publication )

Stem Cells, 2012, 30(9):1863-74

PubMed: 22761013 ( click the link to review the publication )

Carcinogenesis, 2012, 33(3):529-37

PubMed: 22201186 ( click the link to review the publication )

J Biol Chem, 2012, 287(2):893-904

PubMed: 22102280 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47312

PubMed: 23077590 ( click the link to review the publication )

BMC Dev Biol, 2012, 12:21

PubMed: 22846383 ( click the link to review the publication )

Bachelor of Science, 2012, East China Normal University

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM. ^[1] In addition to simulating the actions of insulin, inhibition of GSK-3 by CHIR-99021 (3 μM) increases free cytosolic β-catenin by 1.9-fold, mimicking the canonical Wnt signaling pathway in 3T3-L1 preadipocytes. During any of the first 3 days of differentiation, CHIR-99021 treatment inhibits the preadipocyte differentiation with IC50 of 0.3 μM by blocking induction of CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). ^[2] Unlike lithium chloride and AR-A014418, CHIR-99021 treatment does not reduce the viability of INS-1E cells even at high concentrations. Instead, CHIR-99021 robustly increases the rate of proliferation of INS-1E cells in a dose-dependent manner, and significantly inhibits INS-E cell death induced by high glucose and high palmitate in a concentration-dependent manner. CHIR-99021 promotes primary beta cell replication in isolated rat islets at concentrations as low as 1 μM, with 2-3 fold increase of cell replication at 5 μM of CHIR-99021 treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3-L1	NVXmU2JzTnWwY4Tpc44hSXO\|YYm=	NU\vVlFbOyEQvF2=	NY\zZ41iPCCq	MnvZSG1UVw>?	MnjnTY5pcWKrdIOgdJJm[WSrcH;jfZRmKGSrZn\ldoVvfGmjdHnvci=>	MUixNlA2PTJyMB?=
insulin receptor–expressing CHO-IR	NVi1cmMyTnWwY4Tpc44hSXO\|YYm=	Mnn4OVAxKG6P	MlHaN\|AhdWmw	NYjyN3lQTE2VTx?=	MXfBZ5RqfmG2ZYOgS4x6[2:pZX6gV5lvfGijc3WgLGdUMQ>?	Mn;nNVI3ODZ2OUe=
H4IIE	M1LXWmZ2dmO2aX;uJGF{e2G7	MmLqNVAh\|ryP	MmHENlQhcA>?	M4fWUGROW09?	NF:ydFRT\We3bHH0[ZMh\|rJvY3H0[Y5qdiCjY4Tpeol1gSCjbnSgWGlTTSClb370ZYlvcW6pIIDyc41wfGW{IHHjeIl3cXS7	MXOxOVM2ODF7NR?=
Oct4/Sox2/Klf4-infected MEFs	NHP3b2NHfW6ldHnvckBCe3OjeR?=	MoLXNVAh\|ryP	MX2yPEBl	NHnFUlhFVVOR	MYPQdo9ud3SnczDNSWZ{KHKncILv[5JidW2rbnegWJJidnOmdXPl[EBjgSCRY4S0MEBUd3h{LDDhcoQhU2yoNB?=	NGjwS5IyQTh\|OUC1OS=>
Sca-1+ HPC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTiNkDPxE1?	NEfGeYo3KGR?	NHXldWNFVVOR	MkHCV5lv\XKpaYP0bYNidGy7IIDyc41wfGW\|IGPjZU0yM8LiSGDDJJBzd2yrZnXyZZRqd25iYX7kJINwdG:weTDmc5Ju[XSrb36geI9o\XSqZYKge4l1cCCHR1[=	M{\vR\|IyPjJ2M{S4
HMC1.2	NXvXWJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSzNEDPxE1?	MnTMO\|IhcA>?	NIXVUVRFVVOR	MomwVoVlfWOnczDj[YxtKHO3co\peoFt	NF3pdHozOjB\|OUOwNS=>
Endothelial cell(EC)	NH\1OWxHfW6ldHnvckBCe3OjeR?=	NIjK[3g{KM7:TR?=		NIDGcXlFVVOR	M3TEPXBzd22xdHXzJIVv\G:2aHXsbYFtKGOnbHygLGVEMSCmaX\m[ZJmdnSrYYTpc44>	M{jQbVIzODV{MEC2
PANC1	NGn4PGdCeG:ydH;zbZMhSXO\|YYm=	M2fCeOKhPSEQvF2=	NVr0UI9mPzJiaB?=	MXXEUXNQ	NHq4e3RVemmpZ3Xyd{BidiCjcH;weI91cWNicnXzdI9ve2V?	MkW1NlIzODFzOE[=
INS-1E	NHvZSZVHfW6ldHnvckBCe3OjeR?=	NWnNWoNlOi53IN88US=>	MoCyNlQhcA>?	MYPEUXNQ	MX\JcoR2[2W\|IHGgdoVlfWO2aX;uJI9nKE6SMTDveoVz\XiycnXzd4lwdg>?	MX6yNlQzPzdyNB?=
hiPSC-NPs	NUj5WmViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfFWFE{6oDLzszN	NFvuZW44OiCq	MXjEUXNQ	M3fmd2lv[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc47DqA>?	NE\CbYIzOjZ2Mk[4Oy=>
platelets	NELzPWpHfW6ldHnvckBCe3OjeR?=	MmLBNVAh\|ryP	MXOxOUBucW5?	NFfn[WhFVVOR	NXrsclhxUW6lcnXhd4V{KHSqcn;tZolvNW2nZHnheIVlKHCuYYTlcIV1KGGpZ4Ll[4F1cW:wIHHu[EBCXFBic3XjdoV1cW:w	Mlr0NlMzOzl6N{e=
DN3	MW\GeY5kfGmxbjDBd5NigQ>?	Mkn2NVAh\|ryP	M{jxRVk3KGh?	MoKwSG1UVw>?	MWfJcoNz\WG\|ZYOgZ4VtdCCmZY\lcI9xdWWwdDDhcoQheHKxbHnm[ZJifGmxbh?=	MXGyN\|UzPjl6OR?=
embryonic stem cells (ESC)	NVXSS4MzTnWwY4Tpc44hSXO\|YYm=	NVW2fpd5OyEEtV2=	MYSxNUBl	Mnq5SG1UVw>?	M4CxbHBzd22xdHXzJJNmdGZvcnXu[ZdidCCxZjDuZeOwfmVvdInw[UBud3W\|ZTDlcYJzgW:waXOgd5RmdSClZXzsd{ApTVOFKR?=	NGG5dpAzOzh2M{OxNi=>
H460	NGrTb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HiWFUhyrWP	M3jIOFI1KGh?	M3P2RWROW09?	NH3MSGxRem:vb4Tld{Bk\WyuIIDyc4xq\mW{YYTpc44>	NU\G[ndwOjR\|Nke2PFg>
H157	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYixTXJ6PSEEtV2=	Ml\VNlQhcA>?	MXXEUXNQ	NXzWNI9DWHKxbX;0[ZMh[2WubDDwdo9tcW[ncnH0bY9v	NWHaS2JiOjR\|Nke2PFg>
H460	MkCwRZBweHSxc3nzJGF{e2G7	M{TmSlUhyrWP	MXSyOEBp	M1jCTmROW09?	NVjWWmI1SXS2ZX71ZZRmeyClZXzsJIFxd3C2b4Ppdy=>	NV3oc3Y{OjR\|Nke2PFg>
H157	NGfkRndCeG:ydH;zbZMhSXO\|YYm=	NH:0e2I2KML3TR?=	NF;yV3UzPCCq	NYfiSGZ[TE2VTx?=	NF\5VWxFd2W\|IH7veEB{cWewaX\pZ4FvfGy7IHHm[oVkfCCjcH;weI9{cXN?	NHvNNW4zPDN4N{[4PC=>
A549	NFvsR2hCeG:ydH;zbZMhSXO\|YYm=	NH\GTYQ2KML3TR?=	NWLxVVZZOjRiaB?=	NFu5dIpFVVOR	MVvJcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXN?	MlLZNlQ{Pjd4OEi=
Neural progenitor cells	MYXGeY5kfGmxbjDBd5NigQ>?	NIOxXnE{KM7:TR?=	M1frRlExKGR?	NULZeoI1TE2VTx?=	M4rPTmlv\HWlZYOg[4Vv\XKjdHnvckBw\iCwZYXyZYwheHKxZ3XubZRweiClZXzsdy=>	NH;VOJozPDZ\|OECzOC=>
ES-D3	NHjzfHZEgXSxdH;4bYMhSXO\|YYm=	NIjuc3cyOMLizszN	MknXN{Bl	MorOSG1UVw>?	NXXwcVljUW6mdXPld{Bud2SncnH0[UBkgXSxdH;4bYNqfHlid3n0bEBKSzVyIH;mJFQvQSEQvF2=	M1nuVFI1Pzd7M{[1
ES-CCE	M1XRcGN6fG:2b4jpZ{BCe3OjeR?=	NYPwVJVEOTEEoN88US=>	NGX5epc{KGR?	MmLISG1UVw>?	NWG1PZZ3UW6mdXPld{Bud2SncnH0[UBkgXSxdH;4bYNqfHl?	NYPCZWwxOjR5N{mzOlU>
ES-D3	NXXae2hHTnWwY4Tpc44hSXO\|YYm=	Ml;nOeKh\|ryP	NUPNeHNHOyCm	M3HmW2ROW09?	NXPCe2dNW3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	MYeyOFc4QTN4NR?=
ES-CCE	NFztVm5HfW6ldHnvckBCe3OjeR?=	NHn0Ulk2yqEQvF2=	NULrc2FxOyCm	MY\EUXNQ	NGqzN4ZUfHKxbnfsfUBqdmS3Y3XzJJRp\SCjY4Tpeol1gSCxZjDXcpQw[mW2YT3jZZRmdmmwIIDheIh4[Xl?	NVHET4tKOjR5N{mzOlU>
SW982	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLsTWM2OD1yLkKxOFE3KM7:TR?=	NV\3SG5IW0GQR1XS
GCT	NVnPTYVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTSclQ2UUN3ME2wMlMxPjd{IN88US=>	MnrjV2FPT0WU
769-P	NHHjNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnyTWM2OD1yLkW4OFk6KM7:TR?=	NEj3U\|RUSU6JRWK=
LOXIMVI	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUiwPXVwUUN3ME2wMlU5QDN{IN88US=>	Ml3EV2FPT0WU
D-336MG	NUPsdmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTBwOES2NkDPxE1?	NFfSeZFUSU6JRWK=
S-117	NGXz[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\TTWM2OD1yLkmyNVMyKM7:TR?=	NF\SdodUSU6JRWK=
D-247MG	NIPUOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzHTWM2OD1yLkm0PFUzKM7:TR?=	MmDwV2FPT0WU
TYK-nu	NX;s[Yp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fuRmlEPTB;MT6wO\|kyOiEQvF2=	MV3TRW5ITVJ?
A498	M{fJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFwM{C0Olkh\|ryP	MV7TRW5ITVJ?
BCPAP	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLNN3pOUUN3ME2xMlY3QDl6IN88US=>	M3Xob3NCVkeHUh?=
KYSE-180	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwN{K3PFgh\|ryP	M2nqVHNCVkeHUh?=
MIA-PaCa-2	NEXORZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnmXIJpUUN3ME2xMlc2QTd5IN88US=>	MlrXV2FPT0WU
HCC1395	NYLXepNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTFwN{iyO\|Mh\|ryP	NVLWVXdNW0GQR1XS
RS4-11	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXKcoZnUUN3ME2xMlk2PDF3IN88US=>	MV\TRW5ITVJ?
NCI-H2122	NH3kSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LkeGlEPTB;Mj6yO\|Y5PCEQvF2=	NEDpRVJUSU6JRWK=
SNU-423	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJwNEm3PFch\|ryP	NFnVR2hUSU6JRWK=
SK-LMS-1	M4LsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HuSmlEPTB;Mj62OFEzQCEQvF2=	MYXTRW5ITVJ?
RPMI-7951	NWL0b\|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJwN{CxPVMh\|ryP	MWjTRW5ITVJ?
COLO-829	M3znXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;xTWM2OD1{Lke2OVQh\|ryP	M4TJUHNCVkeHUh?=
SCC-9	M3jqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJwOUW0PFUh\|ryP	MWPTRW5ITVJ?
A704	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTNwMEixNkDPxE1?	MWDTRW5ITVJ?
HOP-62	M{LKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTNwM{[wOVQh\|ryP	NF7MfYlUSU6JRWK=
HCC1569	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHNTWM2OD1\|LkS4N\|A2KM7:TR?=	Ml:5V2FPT0WU
A172	NYjReGZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTNwN{W0PVgh\|ryP	M4j6bXNCVkeHUh?=
MOLT-16	M4S1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\GTWM2OD1\|Lki4OVU3KM7:TR?=	MkjQV2FPT0WU
TE-15	NXm2PJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTNwOUWzOFMh\|ryP	NIK1V3lUSU6JRWK=
OE19	NXTwfG84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvBSWN[UUN3ME2zMlk3PDVzIN88US=>	NH3YSI5USU6JRWK=
MHH-ES-1	NILaOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTRwMES1OFUh\|ryP	NEnMfY9USU6JRWK=
NKM-1	NGK2OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLtNZU{UUN3ME20MlE{QTdzIN88US=>	NFnqRXdUSU6JRWK=
RCC10RGB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4CxNmlEPTB;ND6yPVQ4QSEQvF2=	M1TsTnNCVkeHUh?=
BxPC-3	NUjR[VRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPBTWM2OD12LkewN\|kyKM7:TR?=	NVTkVmE1W0GQR1XS
ALL-PO	M3LQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\jc3ZLUUN3ME20Mlg{QDV6IN88US=>	M3vKWXNCVkeHUh?=
SK-OV-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTVTWM2OD12Lkm5N\|Qh\|ryP	MWLTRW5ITVJ?
SW1710	NUnWcHlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXxTWM2OD13LkSyOFU3KM7:TR?=	MYHTRW5ITVJ?
NCI-H2452	NHfqVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHrO2lKSzVyPUWuOFU3OjhizszN	NEi2VoJUSU6JRWK=
D-392MG	NULwTZN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLEW4tKSzVyPUWuOFkyPDVizszN	MYHTRW5ITVJ?
LB2518-MEL	NXL0O2liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moq0TWM2OD13LkeyOlI4KM7:TR?=	MWnTRW5ITVJ?
BL-41	NWPTNGcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrmTWM2OD13LkixNlY3KM7:TR?=	MVfTRW5ITVJ?
WM-115	NF;1OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHJdoxKSzVyPUWuPFE2ODlizszN	NX24eYpyW0GQR1XS
SK-MEL-2	NV7kbVY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkWxTWM2OD14LkO4N\|Q1KM7:TR?=	MoLiV2FPT0WU
CGTH-W-1	M1HtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTZwNEG3JO69VQ>?	MXnTRW5ITVJ?
BB65-RCC	NH3zeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\6XYZKSzVyPU[uOVMyQTVizszN	M2XLWnNCVkeHUh?=
CAL-85-1	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HJNmlEPTB;Nj62NFk{PiEQvF2=	NVLoSJVDW0GQR1XS
RT-112	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjyTWM2OD15LkG2OFU3KM7:TR?=	NELGeGhUSU6JRWK=
MC116	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\QOWVKSzVyPUeuNlg3QTFizszN	NYrtdXFQW0GQR1XS
G-361	NG\P[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHqbXdKSzVyPUeuOFY2PjFizszN	NFrRNJVUSU6JRWK=
SW1417	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfJTGFxUUN3ME23MlY1PTh2IN88US=>	M{D3[HNCVkeHUh?=
MV-4-11	NIDE[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jpNGlEPTB;OD61OFMxPCEQvF2=	M1v0UXNCVkeHUh?=
CAL-72	M4XXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTKVW5QUUN3ME24Mlc3OTF\|IN88US=>	MWrTRW5ITVJ?
MKN28	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDORVBKSzVyPUiuPFg2OTZizszN	NVPrfXFvW0GQR1XS
MEG-01	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF6wcWhKSzVyPUiuPVkxPDNizszN	MVfTRW5ITVJ?
ACHN	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LIOWlEPTB;OT6zNFU1PiEQvF2=	M3Gwc3NCVkeHUh?=
NCI-H1755	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvtTWM2OD17LkO5PVg3KM7:TR?=	NVzJeWU4W0GQR1XS
NCI-H64	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4L3RWlEPTB;OT60NlI2PSEQvF2=	NVLXZ3Y{W0GQR1XS
COLO-205	NU\nOZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmWyTWM2OD17LkSzPFIyKM7:TR?=	NHrIb3RUSU6JRWK=
CTV-1	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFmxcFJKSzVyPUmuOFM5QTRizszN	NX\sW3l4W0GQR1XS
U-2-OS	NWjGfZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTlwNEWwNFYh\|ryP	MV;TRW5ITVJ?
LB996-RCC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrlTWM2OD17LkWyN\|k4KM7:TR?=	NYq0[\|JvW0GQR1XS
SK-N-DZ	M2K4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nhU2lEPTB;OT62OVc1OiEQvF2=	MoLFV2FPT0WU
EFM-19	NXrPOmsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTlwN{W1OlYh\|ryP	MkDJV2FPT0WU
DBTRG-05MG	NH\xc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTlwN{e3O{DPxE1?	NEDJOGFUSU6JRWK=
U-118-MG	NVvjU2RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTlwOUS0OFQh\|ryP	MUPTRW5ITVJ?
LB1047-RCC	NILmNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjIR2VKSzVyPUmuPVk4QThizszN	M1fDV3NCVkeHUh?=
NCI-H28	M1LTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;GPGlEPTB;MUCuOFQyOyEQvF2=	NIHKXmFUSU6JRWK=
MZ2-MEL	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTFyLkS2O\|ch\|ryP	M2qwcHNCVkeHUh?=
M059J	NVSwSnRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFyLk[xNFIh\|ryP	Mmi4V2FPT0WU
HT-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nnZWlEPTB;MUCuOlE4QSEQvF2=	NIf2NHpUSU6JRWK=
SNU-387	M2PpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFyLkeyN\|Uh\|ryP	M2L2RXNCVkeHUh?=
NCI-H526	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYP0O3V3UUN3ME2xNU4yOzZ3IN88US=>	NF3CPIhUSU6JRWK=
HEL	NUW5SIVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PJ[2lEPTB;MUGuOlU4QSEQvF2=	MULTRW5ITVJ?
PA-1	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX0eXpKSzVyPUGxMlk{KM7:TR?=	MlXOV2FPT0WU
PC-14	M{nzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF{LkOyOEDPxE1?	NVfnbFRUW0GQR1XS
C8166	M16zNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF\|LkKzNVgh\|ryP	MVPTRW5ITVJ?
NCI-H82	M{fCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXKzTWNQUUN3ME2xN{4zQTB7IN88US=>	MnnoV2FPT0WU
DSH1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jQSmlEPTB;MUOuN\|g4QSEQvF2=	MX3TRW5ITVJ?
T98G	NIL0OFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF\|LkS3NVch\|ryP	NVT3clhsW0GQR1XS
KU812	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jkN2lEPTB;MUOuOVE4PSEQvF2=	MXfTRW5ITVJ?
SW48	NUXxR\|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1W2[GlEPTB;MUOuO\|I3PSEQvF2=	NYCydWliW0GQR1XS
MEL-HO	NX;pXoJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K0eGlEPTB;MUOuPFgzQSEQvF2=	M{nDVHNCVkeHUh?=
SF539	M2Dofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnq1TWM2OD1zND6wNVE3KM7:TR?=	MoPmV2FPT0WU
NB1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH25R2VKSzVyPUG0MlE6OzVizszN	NXqwU\|JHW0GQR1XS
ST486	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTF2LkKyOVEh\|ryP	MXjTRW5ITVJ?
LoVo	M4PRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTF3LkK2OVkh\|ryP	NVf2XYxpW0GQR1XS
NH-12	M4njZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPYd4g5UUN3ME2xOk4xODl5IN88US=>	MWTTRW5ITVJ?
CCRF-CEM	M{\3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LXcGlEPTB;MU[uOlcxOiEQvF2=	M3nFVXNCVkeHUh?=
Daudi	NVLNZ3R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTpc\|JKSzVyPUG3MlYyPDlizszN	NYn5N5BWW0GQR1XS
SIMA	M37kW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vEdGlEPTB;MUeuPVEyQCEQvF2=	NWf1[pZIW0GQR1XS
8305C	NVzXNVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzTXo1KSzVyPUG4MlU{ODVizszN	MlPqV2FPT0WU
EM-2	NFfBSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jwWmlEPTB;MUiuOlI1QCEQvF2=	NYrsT4tyW0GQR1XS
SNU-449	M{CzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF6LkexOUDPxE1?	MWHTRW5ITVJ?
A101D	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfkUXRKSzVyPUG5MlI1OyEQvF2=	NHX0PYpUSU6JRWK=
MHH-NB-11	M2PUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jPRWlEPTB;MUmuOVM1OiEQvF2=	M3HUfnNCVkeHUh?=
Becker	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7LTWM2OD1{MD6xO\|c4KM7:TR?=	NV3NeIRqW0GQR1XS
NCI-H727	NFXOc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTJyLkKxOlkh\|ryP	NHLoNldUSU6JRWK=
HCC1187	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7KTWM2OD1{MD6zOVg6KM7:TR?=	NXnEdFJRW0GQR1XS
KYSE-450	M4jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS1TWM2OD1{MT61N\|U1KM7:TR?=	NX\Kb3NpW0GQR1XS
SK-MEL-28	NXr6RnBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXMNoFKSzVyPUKxMlY5PjNizszN	MmrIV2FPT0WU
BPH-1	NXXOc4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJzLkewN\|Uh\|ryP	NGfmNWRUSU6JRWK=
EoL-1-	NVLDTIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJzLkizPFUh\|ryP	M1jpc3NCVkeHUh?=
TGBC24TKB	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLrSFZKSzVyPUKxMlg6PTdizszN	MmiyV2FPT0WU
KARPAS-299	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\yTWM2OD1{Mj6xPVU1KM7:TR?=	MXzTRW5ITVJ?
SW684	MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LFOWlEPTB;MkKuNlg2QCEQvF2=	NFX3O2FUSU6JRWK=
RXF393	NUTvVYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJ{Lk[wOlgh\|ryP	NHvKTYhUSU6JRWK=
LS-513	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;WdZhlUUN3ME2yNk43OTl{IN88US=>	MY\TRW5ITVJ?
KURAMOCHI	NX\seIRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfzOoNKSzVyPUKyMlcxPjlizszN	NG\le4NUSU6JRWK=
GI-1	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJ{Lke4OFEh\|ryP	NYLDeHVpW0GQR1XS
M14	NF62V2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFWwWYdKSzVyPUKzMlEyOzJizszN	NYDFT3FiW0GQR1XS
REH	NGHqToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HwXGlEPTB;MkOuNVY6QSEQvF2=	NELVXYNUSU6JRWK=
K5	MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M173SWlEPTB;MkOuOVQ5PiEQvF2=	NUS1eGE3W0GQR1XS
PANC-10-05	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;kTWM2OD1{ND6wPFk5KM7:TR?=	M{DjcnNCVkeHUh?=
HMV-II	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnLNHNKSzVyPUK0MlIyPjNizszN	NU\LVVRTW0GQR1XS
NCI-H1963	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELnN29KSzVyPUK0MlI5OzlizszN	NV;hNJViW0GQR1XS
LU-139	M2nmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XhT2lEPTB;MkSuPFM2KM7:TR?=	MoT1V2FPT0WU
KASUMI-1	NYjodVVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJ2LkmzNlgh\|ryP	NEi2VXNUSU6JRWK=
RO82-W-1	M4jZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrac3FKSzVyPUK2Mlc{PzdizszN	MkPOV2FPT0WU
NCI-H1770	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3n2N2lEPTB;Mk[uPFk5PiEQvF2=	Ml;YV2FPT0WU
SNG-M	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLNTWM2OD1{Nz6yNlcyKM7:TR?=	MUXTRW5ITVJ?
KLE	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[0NGZxUUN3ME2yO{4zPTZ3IN88US=>	MmG2V2FPT0WU
NCI-H2170	M1\6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;vN5RvUUN3ME2yO{42Ojh{IN88US=>	M{DS[nNCVkeHUh?=
COLO-792	NEPifXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DIUmlEPTB;MkeuO\|czQCEQvF2=	NFKzToRUSU6JRWK=
ES8	MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7wTWM2OD1{Nz63PFE1KM7:TR?=	NF7RS4dUSU6JRWK=
MC-CAR	NGXSS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHpclZKSzVyPUK3Mlc6ODdizszN	NHjpPIhUSU6JRWK=
SU-DHL-1	NFrPdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlz1TWM2OD1{Nz65OFc1KM7:TR?=	NUX5ZY97W0GQR1XS
OAW-28	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TJfGlEPTB;MkiuNFA2OiEQvF2=	NXfUd2k3W0GQR1XS
C32	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\mVXJKSzVyPUK4MlA5OjZizszN	NIjNSWNUSU6JRWK=
SW872	NEPUelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\NTWM2OD1{OD61N\|I3KM7:TR?=	NEDTW\|RUSU6JRWK=
JiyoyeP-2003	M4fR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;uc2lEPTB;MkmuOlcyQSEQvF2=	M3\kNXNCVkeHUh?=
A204	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ryZmlEPTB;MkmuOlgzQCEQvF2=	MYDTRW5ITVJ?
IST-MES1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jSW2lEPTB;MkmuO\|A6OiEQvF2=	NETnV4NUSU6JRWK=
LCLC-103H	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NED2TnhKSzVyPUOwMlIxPTlizszN	MUjTRW5ITVJ?
CAKI-1	NXz4UJBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILRWWxKSzVyPUOwMlI3PTZizszN	NIqzdFZUSU6JRWK=
NALM-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vKPWlEPTB;M{CuOFk3PSEQvF2=	MUXTRW5ITVJ?
SK-MM-2	NU\VVFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XISWlEPTB;M{CuPVc6OiEQvF2=	MkPuV2FPT0WU
LB373-MEL-D	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jzRmlEPTB;M{GuNFA1PyEQvF2=	MlT4V2FPT0WU
CAS-1	M1;Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\uTWM2OD1\|MT63OlY2KM7:TR?=	MXzTRW5ITVJ?
KNS-42	NEnaW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3i5bGlEPTB;M{GuPFY3OiEQvF2=	MVPTRW5ITVJ?
SW948	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnydIxTUUN3ME2zNk44PTR6IN88US=>	NH\kdYdUSU6JRWK=
HCC1143	M{DsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\LTWM2OD1\|Mj63PVc6KM7:TR?=	NXHCdZZ4W0GQR1XS
NCI-H1648	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;5[JZKSzVyPUOyMlg1PjdizszN	NG\Ed29USU6JRWK=
RVH-421	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LRfWlEPTB;M{OuNVY5KM7:TR?=	NWj3[Gl2W0GQR1XS
KU-19-19	NWLmOHluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojxTWM2OD1\|Mz63OVM1KM7:TR?=	MUDTRW5ITVJ?
PFSK-1	NELKPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTNT21uUUN3ME2zOE46OjRzIN88US=>	NGD2ZVlUSU6JRWK=
TK10	NXztdJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTQTWM2OD1\|NT6xN\|IzKM7:TR?=	MlnHV2FPT0WU
IGROV-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrpTWM2OD1\|NT6zOFE3KM7:TR?=	NYizRm5kW0GQR1XS
EFE-184	M3rQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTN3LkmxO{DPxE1?	MXLTRW5ITVJ?
8505C	NV7xPY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN3LkmyPVQh\|ryP	NUH2WGFrW0GQR1XS
SK-UT-1	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTN4LkOzN\|Eh\|ryP	M4H3OHNCVkeHUh?=
MKN1	NGrUTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHxeVRKSzVyPUO2Mlg1PDRizszN	NEHMOIVUSU6JRWK=
no-10	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moq1TWM2OD1\|OD6xNlk1KM7:TR?=	NETUWpFUSU6JRWK=
HT-144	NInDWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnS[W1jUUN3ME2zPE4zPTd3IN88US=>	M1TibXNCVkeHUh?=
CMK	NVrsd41JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u2PGlEPTB;M{iuOFE3OiEQvF2=	NFHs[nJUSU6JRWK=
KM12	NF\xS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\Ne\|hvUUN3ME2zPE42QTl6IN88US=>	M1;WU3NCVkeHUh?=
HCC2218	NF\VZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7FVIFKSzVyPUSwMlU5PDlizszN	NFf1XXJUSU6JRWK=
BE-13	NXjOb4ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTRzLkS0O\|Mh\|ryP	Mm\2V2FPT0WU
SK-CO-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILlWnlKSzVyPUSxMlc4PTVizszN	NWjNfI5SW0GQR1XS
MPP-89	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\BbGlEPTB;NEGuPVIyOSEQvF2=	M1;CXHNCVkeHUh?=
NY	NVn5UGNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTR{LkG4NFEh\|ryP	M2LvdnNCVkeHUh?=
IST-MEL1	M{PYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml62TWM2OD12Mj62PVM5KM7:TR?=	M3XMcXNCVkeHUh?=
HCT-116	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PzPGlEPTB;NEOuNlA6QSEQvF2=	NEGxO2dUSU6JRWK=
LB831-BLC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[zZlFzUUN3ME20N{43QTdizszN	MUDTRW5ITVJ?
TE-8	NX;tVWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvVZWdKSzVyPUSzMlc5QTVizszN	MWnTRW5ITVJ?
SR	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWGyTGs{UUN3ME20N{45Pjd\|IN88US=>	Mk[5V2FPT0WU
ESS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUWybVZkUUN3ME20OE4zODZ{IN88US=>	NXnHfIhyW0GQR1XS
KYSE-270	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTETWM2OD12NT6wOFM4KM7:TR?=	M2H6bnNCVkeHUh?=
H4	M{PPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTFTWM2OD12NT6zNlk3KM7:TR?=	M4P1WHNCVkeHUh?=
COLO-800	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjFc2dKSzVyPUS1MlU5QThizszN	NIDSSGlUSU6JRWK=
Ramos-2G6-4C10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTR4LkC3OVUh\|ryP	MUjTRW5ITVJ?
no-11	M4PWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPG[VR7UUN3ME20Ok4zODNzIN88US=>	M{fqeXNCVkeHUh?=
UACC-62	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnsTWM2OD12Nj64OlA5KM7:TR?=	MV7TRW5ITVJ?
D-542MG	MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGK0VnRKSzVyPUS3MlQ2QDlizszN	MmT4V2FPT0WU
NCI-H747	NIm2fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjtSmRFUUN3ME20O{44OjZ2IN88US=>	M2\DdnNCVkeHUh?=
HCC2998	M2PIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Lve2lEPTB;NEiuNlk5OiEQvF2=	Mm\RV2FPT0WU
SNB75	NVPSfYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PxWWlEPTB;NEiuOFEyQCEQvF2=	NIfmNmNUSU6JRWK=
COR-L105	M1rzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\kXVJKSzVyPUS4Mlk4OyEQvF2=	NUfQUndYW0GQR1XS
SNU-C1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjXZnJKSzVyPUS5MlMzODdizszN	M2TyO3NCVkeHUh?=
LC4-1	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTR7Lki5NVIh\|ryP	NUnQfYNTW0GQR1XS
KS-1	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rlN2lEPTB;NUCuNlIzPSEQvF2=	MYrTRW5ITVJ?
NCI-H1793	NYDoSpB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTVzLkKzNUDPxE1?	NGj4WWpUSU6JRWK=
NCI-H1650	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTVzLkW4OFkh\|ryP	NGTDPFVUSU6JRWK=
MCF7	M1Prc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;rXWtKSzVyPUWxMlc2PTRizszN	MkXaV2FPT0WU
SK-N-AS	MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XScWlEPTB;NUGuPFI5OSEQvF2=	MUPTRW5ITVJ?
SW837	NXf3SGJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3TcVlKSzVyPUWxMlk4QDVizszN	NWTRNHRbW0GQR1XS
DB	M2C3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXzTWM2OD13MT65PFU2KM7:TR?=	MXHTRW5ITVJ?
CESS	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\jNnkyUUN3ME21Nk4yPDVizszN	MXzTRW5ITVJ?
CHP-126	NHzXWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3u5cWlEPTB;NUOuOVE3QSEQvF2=	NELNRo1USU6JRWK=
COLO-824	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnRPYRIUUN3ME21N{43QTd4IN88US=>	MX\TRW5ITVJ?
MG-63	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTV\|LkmzPFEh\|ryP	Moe3V2FPT0WU
KGN	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PPeWlEPTB;NUOuPVU6KM7:TR?=	NVzSblJzW0GQR1XS
697	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTjWnJKSzVyPUW0MlE2PTVizszN	MWfTRW5ITVJ?
MC-IXC	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPLTWM2OD13ND60N\|Y1KM7:TR?=	NXPYVnpuW0GQR1XS
A375	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTV2LkiwOVkh\|ryP	NYLHWoN4W0GQR1XS
LXF-289	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWm1N2lTUUN3ME21OU42ODZ4IN88US=>	MWHTRW5ITVJ?
ES6	NGDnXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV3Lki4PVkh\|ryP	NWTUUXAyW0GQR1XS
DV-90	NF[2PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXyTWM2OD13NT64PVE4KM7:TR?=	MkDIV2FPT0WU
RCM-1	NXH5clJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfMbVYzUUN3ME21Ok4xODd6IN88US=>	NF\KRohUSU6JRWK=
NCI-H2405	NF7vWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTV4LkG2PVMh\|ryP	MX7TRW5ITVJ?
DoTc2-4510	NX;Me4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfVUXBKSzVyPUW2MlYxPTdizszN	Mn;XV2FPT0WU
RPMI-8866	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\US2JKSzVyPUW3MlI1OTJizszN	MXXTRW5ITVJ?
BV-173	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nSdmlEPTB;NUeuOVE1OiEQvF2=	MlezV2FPT0WU
LCLC-97TM1	NHfVTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zBV2lEPTB;NUmuNFU2OyEQvF2=	MnflV2FPT0WU
HT-1376	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;OTWM2OD13OT6wPVIyKM7:TR?=	NFvjWWVUSU6JRWK=
ACN	NXHLbIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;ucGlEPTB;NUmuNVU5PyEQvF2=	NXvSRXNXW0GQR1XS
LU-134-A	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHzTWM2OD13OT62NFE3KM7:TR?=	MUXTRW5ITVJ?
SiHa	NF;1SYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDSS\|VKSzVyPUW5MlY1QDdizszN	M4LNN3NCVkeHUh?=
EKVX	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTZzLkS5OVgh\|ryP	MonyV2FPT0WU
NMC-G1	NHfDR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\Qc4lKSzVyPU[xMlkzPDJizszN	MUHTRW5ITVJ?
NCI-H1734	NWXk[FhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;UeFRpUUN3ME22NU46PjZ\|IN88US=>	M{fpXHNCVkeHUh?=
K-562	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULyT4FbUUN3ME22Nk4zPDV{IN88US=>	M1z1ZnNCVkeHUh?=
T-24	M3njOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTFVGxKSzVyPU[yMlcyOjZizszN	M3vvPXNCVkeHUh?=
SCH	NVnU[GlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17zPWlEPTB;NkSuNlM2OSEQvF2=	M3TObXNCVkeHUh?=
AN3-CA	NX;MdZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13Ib2lEPTB;NkSuN\|A{PSEQvF2=	MUPTRW5ITVJ?
MFE-296	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y3Z2lEPTB;NkSuOFQ4OyEQvF2=	M3m2TXNCVkeHUh?=
HuCCT1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\1TWM2OD14Nz6wN\|c1KM7:TR?=	MkHQV2FPT0WU
NCI-H1703	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWmxd4I2UUN3ME22PE4yOTdzIN88US=>	MnP6V2FPT0WU
C-4-II	M4XKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHJfHVKSzVyPU[5MlM3ODdizszN	M3XYSHNCVkeHUh?=
NCI-H2342	NGPSN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLqdotCUUN3ME22PU4{QTZzIN88US=>	NHn3NW5USU6JRWK=
Hs-578-T	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGr6NpZKSzVyPUewMlMh\|ryP	MoLqV2FPT0WU
HCC1806	NGX2dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnKOpN6UUN3ME23NU41PTh5IN88US=>	M{XIXHNCVkeHUh?=
EW-16	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfwVItDUUN3ME23NU44PDF3IN88US=>	NEfFZpdUSU6JRWK=
KALS-1	NHTlU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rVN2lEPTB;N{OuOVQ4PSEQvF2=	M{XLbHNCVkeHUh?=
RT4	NWLyXVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXhTWM2OD15Mz61O\|QzKM7:TR?=	NUfNcJgxW0GQR1XS
LS-411N	NXrBR\|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTd2LkK1Nlgh\|ryP	NFHZbpVUSU6JRWK=
SK-MEL-1	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULtXXl3UUN3ME23OU45ODF7IN88US=>	M2LvSXNCVkeHUh?=
8-MG-BA	NFTiO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTd4LkGwPVYh\|ryP	MX\TRW5ITVJ?
HSC-3	NWfrU5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\EPYo1UUN3ME23O{4xOjh{IN88US=>	NFXFZ5pUSU6JRWK=
NB6	NGmx[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUX5cIhQUUN3ME23PE4yOjl7IN88US=>	NVKzVolVW0GQR1XS
PANC-03-27	M1XOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXFTWM2OD15OD60N\|Uh\|ryP	M4S0UXNCVkeHUh?=
KP-N-YS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnMTWM2OD15OD61PFc5KM7:TR?=	MojjV2FPT0WU
SF295	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jKdmlEPTB;N{muPVU2OyEQvF2=	M1GzeHNCVkeHUh?=
HCE-T	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjaNmN[UUN3ME24NE4yPTh6IN88US=>	MUfTRW5ITVJ?
KYSE-410	NGPo[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvFTWM2OD16MD6yPFU4KM7:TR?=	MX3TRW5ITVJ?
NB12	NI\yd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDzZppKSzVyPUiwMlk{PjlizszN	M{jwR3NCVkeHUh?=
NCI-H661	NFLqO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRThzLkO0OEDPxE1?	M1rGWnNCVkeHUh?=
NCI-H1417	NFTFbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3y4RmlEPTB;OEGuOFM3QCEQvF2=	MX7TRW5ITVJ?
KMOE-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRThzLki1N\|Eh\|ryP	MVXTRW5ITVJ?
SW1573	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\tWopKSzVyPUiyMlU5QTNizszN	MYfTRW5ITVJ?
BFTC-905	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{ftZWlEPTB;OESuNFE4OiEQvF2=	MmrpV2FPT0WU
SBC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4i2XGlEPTB;OESuNFIxQCEQvF2=	M4qyfHNCVkeHUh?=
MDA-MB-175-VII	NFztNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG5TWM2OD16NT63OFI3KM7:TR?=	MkfPV2FPT0WU
TE-12	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPYTWM2OD16OT6zO\|QyKM7:TR?=	NHHHR3FUSU6JRWK=
NCI-H650	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2n1OGlEPTB;OEmuPFczPCEQvF2=	MX;TRW5ITVJ?
C-33-A	NGCzWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfwPJRKSzVyPUmwMlU1KM7:TR?=	NWPNVm1mW0GQR1XS
MZ7-mel	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLvTWM2OD17MT6yOlc3KM7:TR?=	NVrBfHVQW0GQR1XS
BOKU	M{nzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULmPHg4UUN3ME25Nk43QTV5IN88US=>	NUf6SXZNW0GQR1XS
CAL-33	NUflXXh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILTT5JKSzVyPUmzMlA3ODFizszN	MkWyV2FPT0WU
23132-87	NFuwc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHr4WFhKSzVyPUmzMlE3QCEQvF2=	MWjTRW5ITVJ?
J82	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T1[GlEPTB;OUOuO\|gyOSEQvF2=	Ml;pV2FPT0WU
MZ1-PC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDBTWM2OD17ND61PVg1KM7:TR?=	MoruV2FPT0WU
MEL-JUSO	NFHDSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTl2Lkm1OEDPxE1?	MWfTRW5ITVJ?
RMG-I	M1XxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTl3LkGwO\|Ih\|ryP	MUnTRW5ITVJ?
A2058	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4q2bGlEPTB;OUWuOFYyPyEQvF2=	NHzVeHpUSU6JRWK=
Caov-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPTTWM2OD17NT62PFUh\|ryP	MWLTRW5ITVJ?
OS-RC-2	M4fXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPOPGl6UUN3ME25O{41PjFizszN	M3PuOXNCVkeHUh?=
MKN7	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPOZmcyUUN3ME25O{44PDN7IN88US=>	M4PCcXNCVkeHUh?=
U-698-M	M3\kOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\RW5pwUUN3ME25PE46PDh7IN88US=>	NXT0RZVWW0GQR1XS
PC-3	NIHUZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjpcm1KSzVyPUm5MlA2PjRizszN	NUDyUm92W0GQR1XS
NCI-H292	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\IOJBKSzVyPUm5MlMxODRizszN	NWXUSJlEW0GQR1XS
IGR-1	NXziZphbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moj2TWM2OD17OT6zNVE6KM7:TR?=	MmXkV2FPT0WU
Mewo	NXPFS2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTl7LkW2NFMh\|ryP	NIDmOlNUSU6JRWK=
LU-65	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXhZ29nUUN3ME2xNFEvODhzIN88US=>	NYfVSZFsW0GQR1XS
Saos-2	NWDtPGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2H3emlEPTB;MUCxMlQ{PyEQvF2=	Mor6V2FPT0WU
TE-11	NXnrXYJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O4emlEPTB;MUCxMlczPCEQvF2=	MlXpV2FPT0WU
SK-MES-1	M1LqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXRe\|ZnUUN3ME2xNFEvPzZ{IN88US=>	NUO3N2l3W0GQR1XS
KE-37	NIK1dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zJfGlEPTB;MUCyMlk2KM7:TR?=	M17PcnNCVkeHUh?=
MKN45	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHlTWM2OD1zMEOuOVg1KM7:TR?=	M3O4WnNCVkeHUh?=
UM-UC-3	NVPkN\|JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7ZVJVGUUN3ME2xNFMvQDR{IN88US=>	M3;mfnNCVkeHUh?=
SNU-C2B	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLYPItLUUN3ME2xNFUvODJ\|IN88US=>	MWrTRW5ITVJ?
RPMI-8226	M{XaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXiPXFKSzVyPUGwOk43PzhizszN	MoDmV2FPT0WU
PANC-08-13	M1HZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3njemlEPTB;MUC2Mlg2KM7:TR?=	Mni4V2FPT0WU
NCI-H23	NVj4WJpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH71cHlKSzVyPUGwPE4{PTdizszN	NXP2[45IW0GQR1XS
HOP-92	NFHRUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvNfINKSzVyPUGwPE41PzVizszN	NXvPUmxzW0GQR1XS
FTC-133	NYjGS4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLmTWM2OD1zMEiuOFg5KM7:TR?=	MkDNV2FPT0WU
D-263MG	NIfSeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFyOD65OlEh\|ryP	MYDTRW5ITVJ?
DU-145	NWT3c4FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnu[o5pUUN3ME2xNFkvQTR3IN88US=>	M3[yPHNCVkeHUh?=
A253	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XXSWlEPTB;MUGwMlQ4QSEQvF2=	MkK5V2FPT0WU
HCT-15	MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXj5[HpFUUN3ME2xNVAvPjZzIN88US=>	M4qxTnNCVkeHUh?=
WSU-NHL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4D0PGlEPTB;MUGyMlAyKM7:TR?=	NV;s[Yx1W0GQR1XS
U031	NXzvfVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjUZZBKSzVyPUGxNk4xPjVizszN	Ml;SV2FPT0WU
MDA-MB-157	M1nvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4WyN2lEPTB;MUGyMlQ6KM7:TR?=	NXfYSG5tW0GQR1XS
NEC8	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zLT2lEPTB;MUGyMlYzPCEQvF2=	NVzrTY9HW0GQR1XS
SIG-M5	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHrTWM2OD1zMUOuNVI2KM7:TR?=	NEftcWxUSU6JRWK=
786-0	NYjzOllZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfKVo12UUN3ME2xNVMvPDV\|IN88US=>	M13oN3NCVkeHUh?=
DMS-273	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLUTWM2OD1zMUWuOlE4KM7:TR?=	MVLTRW5ITVJ?
Calu-6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTFzNj63PVgh\|ryP	MX\TRW5ITVJ?
HCC1599	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ixSWlEPTB;MUG3MlE2PiEQvF2=	MWrTRW5ITVJ?
OVCAR-8	M2OyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTFzNz62Olgh\|ryP	NWi3ZXduW0GQR1XS
ATN-1	NGXVeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfQOIZKSzVyPUGxO{45OjhizszN	NUnZb5ZlW0GQR1XS
RKO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:0OGF{UUN3ME2xNVcvQDl6IN88US=>	NYjWSoJYW0GQR1XS
SKG-IIIa	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTFzOD6xNVYh\|ryP	NVzu[nRkW0GQR1XS
SUP-T1	NHvLe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnn[3pCUUN3ME2xNVgvQTV4IN88US=>	NYHtc\|ZJW0GQR1XS
KNS-81-FD	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfOO4kxUUN3ME2xNVkvPDF5IN88US=>	Mk\hV2FPT0WU
OVCAR-3	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELCS2pKSzVyPUGxPU46OTVizszN	M3zy[nNCVkeHUh?=
NCI-N87	M{fw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPR[HNrUUN3ME2xNlEvODR2IN88US=>	MonpV2FPT0WU
HuP-T4	NIHLN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTwTWM2OD1zMkGuOVUh\|ryP	M1rsVXNCVkeHUh?=
KYSE-140	M3T6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFL5SpNKSzVyPUGyNk4yPDFizszN	MX7TRW5ITVJ?
HAL-01	NHvPSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXDbZVKSzVyPUGyNk41QTlizszN	NH;FSo9USU6JRWK=
HT-29	NVPGeXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D0UGlEPTB;MUKyMlc4QCEQvF2=	MXXTRW5ITVJ?
OPM-2	M2fCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnzTWM2OD1zMkOuNVc3KM7:TR?=	NUj6XFRKW0GQR1XS
SW1463	NFmxcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7TUHBnUUN3ME2xNlQvODd5IN88US=>	NU\ZPXU6W0GQR1XS
NCI-H2087	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXSXmdNUUN3ME2xNlQvOjh\|IN88US=>	MXvTRW5ITVJ?
UMC-11	M1zidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIH3XWNKSzVyPUGyOk4xOzhizszN	NWDwXJdyW0GQR1XS
EB-3	NGfxfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\v[mlEPTB;MUK3MlAyOyEQvF2=	NGDveVhUSU6JRWK=
HEC-1	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTF{OT6xPVgh\|ryP	MofBV2FPT0WU
LU-99A	NF7reZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVr1W5NjUUN3ME2xNlkvQTNzIN88US=>	M2PXRXNCVkeHUh?=
VMRC-RCZ	M13LV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XSfWlEPTB;MUOwMlM4PSEQvF2=	MXjTRW5ITVJ?
MFH-ino	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnUTWM2OD1zM{GuNVE1KM7:TR?=	MVXTRW5ITVJ?
HT-1080	NG\QfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;VUolKSzVyPUGzNk4zODRizszN	MVHTRW5ITVJ?
CTB-1	NH7KRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj5[FJKSzVyPUGzNk45QTdizszN	NUDuW\|FRW0GQR1XS
Capan-2	NWHNfXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\1O2lEPTB;MUOzMlk4PSEQvF2=	NF7Pe2dUSU6JRWK=
BB30-HNC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPNN3N2UUN3ME2xN\|QvOTF4IN88US=>	M4LheHNCVkeHUh?=
CP50-MEL-B	NFrYZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\oSJhKSzVyPUGzOE4zKM7:TR?=	NXjjNFA{W0GQR1XS
JEG-3	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LTfmlEPTB;MUO0MlM2QSEQvF2=	Mn3QV2FPT0WU
NCI-H1437	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTF\|ND61PUDPxE1?	MX\TRW5ITVJ?
NOS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfndZRzUUN3ME2xN\|QvPzZ3IN88US=>	NULEN2llW0GQR1XS
G-402	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NES1[o9KSzVyPUGzOU4zQTVizszN	MV7TRW5ITVJ?
OAW-42	NHLWdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILyfJdKSzVyPUGzO{45PTZizszN	NGO3b2hUSU6JRWK=
Ca-Ski	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\kTWM2OD1zM{iuPFMyKM7:TR?=	MYPTRW5ITVJ?
BHT-101	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXRbm5KSzVyPUG0NE4zODhizszN	NWDRPYM1W0GQR1XS
OVCAR-4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPFTWM2OD1zNECuO\|Q6KM7:TR?=	MnnIV2FPT0WU
Detroit562	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;kRoFKSzVyPUG0NU41PjZizszN	NGT3ZXVUSU6JRWK=
OCI-AML2	NFL0UlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHrWWVKSzVyPUG0NU42ODdizszN	NVLqe\|FjW0GQR1XS
OE33	NEDCWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2W3emlEPTB;MUSxMlc6QCEQvF2=	MkniV2FPT0WU
YKG-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTF2Mj64PFkh\|ryP	NEO0PG5USU6JRWK=
CCF-STTG1	NYXEcoVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTHTWM2OD1zNEOuN\|M1KM7:TR?=	M4[4[nNCVkeHUh?=
NCI-H810	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3q0UWlEPTB;MUSzMlY5PyEQvF2=	NULKSmNyW0GQR1XS
SCC-25	NWHwWJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTkfFlKSzVyPUG0OE4xODVizszN	MYDTRW5ITVJ?
HTC-C3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTF2NT6wO\|Uh\|ryP	MnPQV2FPT0WU
G-401	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF2NT64N\|Uh\|ryP	MnnFV2FPT0WU
OMC-1	NIXvcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF2NT65Olch\|ryP	M3Tad3NCVkeHUh?=
LK-2	NFHsU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF2Nz6xOFMh\|ryP	M{fDTnNCVkeHUh?=
SW13	M33RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4T4bmlEPTB;MUS3MlI2OyEQvF2=	NH7NOVNUSU6JRWK=
BB49-HNC	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4mzbWlEPTB;MUS3MlQxPCEQvF2=	NGPHfnVUSU6JRWK=
DMS-114	NGqze3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jIZWlEPTB;MUS3MlQ1OSEQvF2=	NVvlUJNrW0GQR1XS
GCIY	NHHpTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPub4FKSzVyPUG0O{44QTdizszN	M3X2e3NCVkeHUh?=
GAMG	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTF2OD6yOFch\|ryP	M4PtZnNCVkeHUh?=
KYSE-520	NETm[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXIO49KSzVyPUG0PE42PCEQvF2=	NVvMRVlDW0GQR1XS
LB647-SCLC	NIfo[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjBTWM2OD1zNEiuOVYzKM7:TR?=	MnOyV2FPT0WU
639-V	NXzKbYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnkTWM2OD1zNEiuO\|A2KM7:TR?=	MlfVV2FPT0WU
TE-9	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f0fmlEPTB;MUS5MlQ1OyEQvF2=	NWO5UXFrW0GQR1XS
Caov-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTF2OT63NVQh\|ryP	MnzJV2FPT0WU
L-540	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\VXIozUUN3ME2xOFkvPzVizszN	MYXTRW5ITVJ?
NCI-H748	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTF3MD6yNFkh\|ryP	MVrTRW5ITVJ?
GDM-1	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFyzNppKSzVyPUG1NU4yOzVizszN	MVTTRW5ITVJ?
GAK	M{KwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;kTWM2OD1zNUGuN\|c1KM7:TR?=	NYDrcGg2W0GQR1XS
AsPC-1	NH3xUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF3Mj63OlQh\|ryP	NXLiS41{W0GQR1XS
MDA-MB-361	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVuySoZmUUN3ME2xOVMvOTZ2IN88US=>	NH20dXZUSU6JRWK=
TT	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXYTWRrUUN3ME2xOVMvPDlizszN	NHXlVXNUSU6JRWK=
Calu-1	NG\RcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTF3ND6wNFMh\|ryP	NIXKXYdUSU6JRWK=
RERF-LC-MS	M2DrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF3ND63O\|Ih\|ryP	NETueJdUSU6JRWK=
DK-MG	NG\3coJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTF3NT6xPFMh\|ryP	M2LsTnNCVkeHUh?=
CAL-120	NUXMd\|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fQNmlEPTB;MUW1MlgzOSEQvF2=	MUnTRW5ITVJ?
HCC1419	NVHvRnp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzPTWM2OD1zNU[uNFc4KM7:TR?=	MlvpV2FPT0WU
DG-75	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTF3Nj62PVQh\|ryP	NYjJ[mV1W0GQR1XS
HCC38	MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvH[mFVUUN3ME2xOVcvOzZ7IN88US=>	Ml;MV2FPT0WU
HCC70	NETscW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUns[VBoUUN3ME2xOVkvOjR{IN88US=>	M3jSVXNCVkeHUh?=
ES4	NV\kW\|NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzLbZJKSzVyPUG1PU4{QTZizszN	MWfTRW5ITVJ?
NCI-H2052	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXXfoZQUUN3ME2xOVkvPTh\|IN88US=>	MXjTRW5ITVJ?
EFO-27	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe1VZNKUUN3ME2xOlAvPTh2IN88US=>	NYLuemc3W0GQR1XS
CAL-62	NUTlcXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfZR2VGUUN3ME2xOlIvPjF\|IN88US=>	MUXTRW5ITVJ?
CHP-212	NU\E[YJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHITWM2OD1zNkOuOlI3KM7:TR?=	NH3BXItUSU6JRWK=
AU565	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XFZ2lEPTB;MU[zMlY1KM7:TR?=	MXXTRW5ITVJ?
Ca9-22	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF4ND6zNlEh\|ryP	MVTTRW5ITVJ?
EFO-21	NU\GN3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTCfHVjUUN3ME2xOlUvPDVizszN	MYHTRW5ITVJ?
KINGS-1	M3jhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELFb2RKSzVyPUG2O{4{PTRizszN	M{\KTHNCVkeHUh?=
JVM-2	NHjJPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLETWM2OD1zNkeuOFUyKM7:TR?=	MnfCV2FPT0WU
OVCAR-5	NIe2XIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF4OD6zNFkh\|ryP	MX7TRW5ITVJ?
Calu-3	NYXyOFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrQemZCUUN3ME2xOlgvOzFzIN88US=>	M1S1XHNCVkeHUh?=
CP66-MEL	NHH6WFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\PfGlEPTB;MU[4MlQyPSEQvF2=	M4nTfnNCVkeHUh?=
KYSE-150	NHL4TFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTF4OT62N\|Yh\|ryP	NUHSeZZkW0GQR1XS
Daoy	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1KxV2lEPTB;MU[5Mlg6OSEQvF2=	NFW4SIlUSU6JRWK=
HUTU-80	NXrxSmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7nTWM2OD1zN{GuNFMzKM7:TR?=	MXTTRW5ITVJ?
SW620	MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzkZ3JKSzVyPUG3NU42OzVizszN	MXfTRW5ITVJ?
HuO-3N1	NIm5SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTF5Mj6yO\|Mh\|ryP	NEW2NnhUSU6JRWK=
HH	NX7lR5JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGOwN4FKSzVyPUG3N{45PDhizszN	MnPJV2FPT0WU
ME-180	NGW1OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrXVlRSUUN3ME2xO\|QvODF4IN88US=>	NVTjfmJlW0GQR1XS
SW756	NU\heotNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTF5ND64OlMh\|ryP	M1HqSnNCVkeHUh?=
LNCaP-Clone-FGC	M3OzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF5NT64OlEh\|ryP	MYfTRW5ITVJ?
YT	M1PTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rUR2lEPTB;MUe2MlM6QSEQvF2=	M2PmcnNCVkeHUh?=
EW-3	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkD0TWM2OD1zN{[uOVU2KM7:TR?=	MYnTRW5ITVJ?
COLO-741	M4\jOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLkTWM2OD1zN{euOVYyKM7:TR?=	NYfwfXBIW0GQR1XS
SK-NEP-1	NIf3XGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\D[JhUUUN3ME2xO\|cvQDB4IN88US=>	M2W2c3NCVkeHUh?=
NB10	NF;JSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7NbIFvUUN3ME2xO\|cvQDR4IN88US=>	M1;UWXNCVkeHUh?=
SF126	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jxS2lEPTB;MUe5MlQ{OiEQvF2=	NYnQTWt1W0GQR1XS
NCI-H522	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rsdGlEPTB;MUixMlA2QSEQvF2=	MnLXV2FPT0WU
PSN1	NIqxXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D2d2lEPTB;MUixMlY3KM7:TR?=	NWizZ25vW0GQR1XS
GI-ME-N	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv3SXlKSzVyPUG4NU43PzJizszN	NWHyOJBFW0GQR1XS
SBC-5	M3jOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PCTGlEPTB;MUixMlk{PCEQvF2=	NFPzc3lUSU6JRWK=
ONS-76	NGj0WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfjTWM2OD1zOEKuN\|g4KM7:TR?=	M3nDenNCVkeHUh?=
LOUCY	NGW1S\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLCTIc5UUN3ME2xPFIvPjh6IN88US=>	MVPTRW5ITVJ?
SN12C	M4DhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;xTWM2OD1zOEKuPFI6KM7:TR?=	MXzTRW5ITVJ?
A427	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTF6ND62N\|Eh\|ryP	NYL4cot{W0GQR1XS
DOK	NFjsZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnHTWM2OD1zOESuOlQ{KM7:TR?=	MknmV2FPT0WU
MDA-MB-415	NFnBPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHmTWM2OD1zOESuOlUyKM7:TR?=	Ml2wV2FPT0WU
MRK-nu-1	NUTzUpFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTF6ND65O\|Ih\|ryP	NX;RU217W0GQR1XS
LB2241-RCC	NGfTToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XZTGlEPTB;MUi1MlE1PSEQvF2=	Mn\ZV2FPT0WU
NCI-H1563	NHP2UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvuWmVKSzVyPUG4OU4zODlizszN	NHzENnZUSU6JRWK=
MDA-MB-453	NFfCN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTJSJB3UUN3ME2xPFYvQTRzIN88US=>	MYfTRW5ITVJ?
MONO-MAC-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHFbGtKSzVyPUG4O{4{QTJizszN	NHnxb3dUSU6JRWK=
CAPAN-1	NFrHb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;NN2lEPTB;MUi3MlQ2OyEQvF2=	NXmwToJEW0GQR1XS
SK-LU-1	NYnyXVVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPUTWM2OD1zOEiuOFI5KM7:TR?=	NX3MeXdsW0GQR1XS
NCI-H1299	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny0TWM2OD1zOEiuO\|E6KM7:TR?=	MVvTRW5ITVJ?
KG-1	NVfMT3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXO0S\|Z[UUN3ME2xPFkvPzl6IN88US=>	MkXWV2FPT0WU
ETK-1	M3vhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4P4UWlEPTB;MUmwMlE5OSEQvF2=	M3n2WnNCVkeHUh?=
NCI-H838	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HucGlEPTB;MUmwMlM1KM7:TR?=	MlrJV2FPT0WU
HCE-4	NF35U2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjlR4J4UUN3ME2xPVAvQTl{IN88US=>	NHf6T2NUSU6JRWK=
A2780	NXfMTZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTF7Mj64PVEh\|ryP	NFizb5VUSU6JRWK=
COLO-668	Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkD3TWM2OD1zOUOuNVU4KM7:TR?=	MkHJV2FPT0WU
HGC-27	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjoTWM2OD1zOUWuOVM5KM7:TR?=	Mlv6V2FPT0WU
SW1088	NH\5WoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTF7NT62O\|ch\|ryP	MkDtV2FPT0WU
KOSC-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTF7NT64NVgh\|ryP	MWnTRW5ITVJ?
TE-1	NUPxN2tNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrwTWM2OD1zOU[uNlYh\|ryP	MYPTRW5ITVJ?
SW780	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\DTWM2OD1zOU[uO\|M1KM7:TR?=	MWfTRW5ITVJ?
22RV1	Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvuT\|JKSzVyPUG5O{41OjRizszN	MWXTRW5ITVJ?
IA-LM	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPzTWM2OD1zOUeuPFIzKM7:TR?=	NITIOI1USU6JRWK=
TE-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv6TWM2OD1zOUiuNFM{KM7:TR?=	MnXqV2FPT0WU
JVM-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fWbGlEPTB;MUm4MlQyQSEQvF2=	NXrQW3Y4W0GQR1XS
HT55	NIrq[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXK1[ZpLUUN3ME2xPVkvOTl{IN88US=>	MY\TRW5ITVJ?
QIMR-WIL	NEDDcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlP6TWM2OD1{MECuNVE3KM7:TR?=	M2nFdnNCVkeHUh?=
SJRH30	M37C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJyMD61NVUh\|ryP	NV;EcI04W0GQR1XS
COLO-679	NHXGR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\ndWlEPTB;MkCwMlg2QSEQvF2=	MoDYV2FPT0WU
MDA-MB-231	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfDe3p4UUN3ME2yNFAvQTB{IN88US=>	M3zQOXNCVkeHUh?=
MFM-223	NVrFPHhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXa[nVxUUN3ME2yNFEvPTh5IN88US=>	NEXRTYxUSU6JRWK=
MFE-280	M3LvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVz1OlVlUUN3ME2yNFEvQTZzIN88US=>	MnrsV2FPT0WU
LAMA-84	M37DNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzpN2xKSzVyPUKwNk4xPzNizszN	Mlm1V2FPT0WU
LS-1034	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJyMj61OVMh\|ryP	Ml7DV2FPT0WU
NCI-H345	M2TKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHOWWpKSzVyPUKwN{4xOjdizszN	NW\EZW5JW0GQR1XS
KYSE-70	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3ezRWlEPTB;MkCzMlg4QSEQvF2=	MmTIV2FPT0WU
EGI-1	NGSxToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHnTWM2OD1{MESuPFM{KM7:TR?=	NIn4NYZUSU6JRWK=
RPMI-2650	NWi3b\|hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3UT5EzUUN3ME2yNFUvPDZ5IN88US=>	M3rzOHNCVkeHUh?=
NCI-H1651	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTJyNj63N{DPxE1?	NVPVV4x5W0GQR1XS
HPAF-II	NHuyfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M36wT2lEPTB;MkC5MlY4OSEQvF2=	NWXYXIRxW0GQR1XS
NUGC-3	NIDI[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2O5U2lEPTB;MkC5MlY4QCEQvF2=	MmXyV2FPT0WU
DJM-1	M37hdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDZbndsUUN3ME2yNFkvQDl5IN88US=>	MV3TRW5ITVJ?
MHH-PREB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rFXmlEPTB;MkGwMlM5OSEQvF2=	MofBV2FPT0WU
EW-18	NHHIT\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHiTWM2OD1{MUCuO\|Y{KM7:TR?=	MUfTRW5ITVJ?
BT-20	M4LPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFn2PGNKSzVyPUKxNE46QDZizszN	M2jXV3NCVkeHUh?=
A431	M{XET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLzWIlyUUN3ME2yNVEvOjl7IN88US=>	Ml;0V2FPT0WU
TCCSUP	NVT5S2lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYj6bYpHUUN3ME2yNVEvPTN\|IN88US=>	NFyxUFRUSU6JRWK=
HO-1-N-1	NYDxcXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPpTWM2OD1{MUKuPFk1KM7:TR?=	NGToSm5USU6JRWK=
NCI-H69	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XiPGlEPTB;MkG0MlE5PSEQvF2=	M2LIdXNCVkeHUh?=
ES7	M1fURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrJNotUUUN3ME2yNVQvQDd6IN88US=>	MmnGV2FPT0WU
C3A	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJzNT61O\|Uh\|ryP	NXHz[Y9IW0GQR1XS
UACC-257	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fvR2lEPTB;MkG3MlQ{KM7:TR?=	NWi2XGNNW0GQR1XS
DMS-153	NU\6dFduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HXPWlEPTB;MkG3Mlg{PiEQvF2=	M4fsOHNCVkeHUh?=
LB771-HNC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEOxOnVKSzVyPUKxO{45QTNizszN	NFHBXm5USU6JRWK=
HOS	Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nzeWlEPTB;MkG4Mlkh\|ryP	M4noeHNCVkeHUh?=
THP-1	NH7BTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrnSnoxUUN3ME2yNVkvPjB4IN88US=>	NXO1TZVvW0GQR1XS
SCC-4	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTWbldOUUN3ME2yNlAvOzV\|IN88US=>	M2jEUnNCVkeHUh?=
SCC-3	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ{MD61O\|ch\|ryP	M3[3WXNCVkeHUh?=
BC-1	NGK1O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYWzUmVGUUN3ME2yNlAvPzl7IN88US=>	Ml;pV2FPT0WU
NCI-H1618	M{n5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPQTWM2OD1{MkGuNFE5KM7:TR?=	MoXLV2FPT0WU
CaR-1	M4Ttfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LBS2lEPTB;MkKxMlI2OSEQvF2=	MlvWV2FPT0WU
NCI-H1355	NGrYbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXva[3hQUUN3ME2yNlEvOzd5IN88US=>	NFniUpNUSU6JRWK=
NCI-H1993	NHezZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDrO4lKSzVyPUKyNk4zOzlizszN	MVfTRW5ITVJ?
NCI-H1623	M3P0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDnTolKSzVyPUKyNk4{QDlizszN	MnTuV2FPT0WU
AGS	NF30S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJ{Mj61NlMh\|ryP	NYTEV4E5W0GQR1XS
SAS	M2n4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJ{Mz63PVYh\|ryP	M1rpUHNCVkeHUh?=
HCC1937	M2jUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33xVmlEPTB;MkK0MlM5QSEQvF2=	MlfYV2FPT0WU
NCI-H209	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILmfnJKSzVyPUKyOk42OyEQvF2=	MlXCV2FPT0WU
NCI-H322M	NWfCTGpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[xTWM2OD1{MkiuNFE6KM7:TR?=	NHTTT\|VUSU6JRWK=
CHL-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TobWlEPTB;MkK4MlE{KM7:TR?=	NInabZVUSU6JRWK=
NCI-H630	M1H6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7FZY1KSzVyPUKzNk45QTdizszN	MmLIV2FPT0WU
5637	NXPVXYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofBTWM2OD1{M{OuNFA{KM7:TR?=	MVXTRW5ITVJ?
MSTO-211H	NIHlZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\LTWM2OD1{M{OuNlc3KM7:TR?=	MXfTRW5ITVJ?
YAPC	M3rNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e0bWlEPTB;MkO0MlI2OyEQvF2=	NVrlOpFoW0GQR1XS
SW1783	M17CZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnr4TWM2OD1{M{SuOFEh\|ryP	MoPIV2FPT0WU
GB-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4r1c2lEPTB;MkO1MlE4PyEQvF2=	NEnubFZUSU6JRWK=
NCI-H520	NWHzNoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLxTWM2OD1{M{WuO\|QyKM7:TR?=	M1ftSXNCVkeHUh?=
NOMO-1	NGHhNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHhNo5kUUN3ME2yN\|YvODJizszN	M2fOSHNCVkeHUh?=
NCCIT	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJ\|Nj64O\|Mh\|ryP	Mnu0V2FPT0WU
SW954	M{LyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTJ\|Nz64Olgh\|ryP	M3r1VnNCVkeHUh?=
MOLT-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUn5PXVKUUN3ME2yOFEvOjB7IN88US=>	NFvTWpVUSU6JRWK=
EB2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\NTWM2OD1{NEGuPVA4KM7:TR?=	M{fDe3NCVkeHUh?=
IPC-298	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHaSWJ[UUN3ME2yOFIvODd{IN88US=>	M1XCXXNCVkeHUh?=
GP5d	M{jtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\Ib\|VKSzVyPUK0Nk43OTZizszN	NHvPSWJUSU6JRWK=
HN	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HFcmlEPTB;MkSyMlk6OSEQvF2=	NHvzbmRUSU6JRWK=
BFTC-909	M3vFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nHOWlEPTB;MkSzMlEyQCEQvF2=	MX3TRW5ITVJ?
ES5	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmewTWM2OD1{NEWuNFM5KM7:TR?=	MkDwV2FPT0WU
SK-HEP-1	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjpTWM2OD1{NE[uNFQ{KM7:TR?=	NFXWXVJUSU6JRWK=
T47D	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJ2Nz6wNVMh\|ryP	MnfHV2FPT0WU
KYSE-510	NIXBeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HNemlEPTB;MkS3MlUyPyEQvF2=	MWnTRW5ITVJ?
LC-1F	NEGyNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXrXlRKUUN3ME2yOFgvOTV4IN88US=>	MnrmV2FPT0WU
NCI-H1693	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJ2OT60PVUh\|ryP	NVHjOlJIW0GQR1XS
COR-L23	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjWSIF{UUN3ME2yOVAvPDF{IN88US=>	MoTmV2FPT0WU
NCI-H2228	NXz4eFBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\mTZBKSzVyPUK1NE45PjRizszN	M4jmfHNCVkeHUh?=
NCI-H460	NWfWR\|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL4eGpKSzVyPUK1NU41OTdizszN	NEn2NG9USU6JRWK=
TGBC1TKB	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXtfoZiUUN3ME2yOVIvQDd3IN88US=>	NFn6enZUSU6JRWK=
NCI-H1304	NIDPXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3ETWM2OD1{NUOuNVU3KM7:TR?=	NIHlc2RUSU6JRWK=
CAL-27	M2rvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrrTWRnUUN3ME2yOVMvPDh3IN88US=>	NF;MR2RUSU6JRWK=
NCI-H187	NVLUSY81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLSTopKSzVyPUK1Ok44PiEQvF2=	MnWzV2FPT0WU
HSC-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fSNWlEPTB;MkW4MlU5PCEQvF2=	NFS5WFBUSU6JRWK=
CAL-39	MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETaXZZKSzVyPUK2NE4zPzJizszN	MnWzV2FPT0WU
HuH-7	M{HiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTJ4MD65PVYh\|ryP	MornV2FPT0WU
MMAC-SF	M2ToW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIO1UW1KSzVyPUK2NU4yQTJizszN	MW\TRW5ITVJ?
VA-ES-BJ	NVvHXFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTJ4MT65NVgh\|ryP	MoTaV2FPT0WU
A673	NX;veFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjU[Wg5UUN3ME2yOlcvODJ3IN88US=>	NVrXfHdCW0GQR1XS
LU-165	NHTCdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zLXmlEPTB;Mk[3Mlk1OSEQvF2=	MY\TRW5ITVJ?
CAL-12T	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUO1NmR[UUN3ME2yOlgvOzZ4IN88US=>	M2rYbnNCVkeHUh?=
RD	NIX6fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJ4OT6xNVkh\|ryP	NHWxNJRUSU6JRWK=
MDA-MB-468	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkWzTWM2OD1{NkmuN\|M{KM7:TR?=	MWDTRW5ITVJ?
LN-405	M{\LW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1q4e2lEPTB;Mk[5MlcxQCEQvF2=	MXzTRW5ITVJ?
MHH-CALL-2	M3;i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJ4OT65NkDPxE1?	NXPFZ2x1W0GQR1XS
ES3	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJ5MD6zOVgh\|ryP	M3vwcnNCVkeHUh?=
SK-MEL-3	M3W0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJ5NT60OVch\|ryP	MX3TRW5ITVJ?
TE-10	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4POXWlEPTB;Mke2MlQ{QSEQvF2=	NF7NcWFUSU6JRWK=
BEN	NV30UnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJ5Nj60OlEh\|ryP	M321e3NCVkeHUh?=
NB69	M334bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGGxU\|ZKSzVyPUK3O{41ODVizszN	M{TRWnNCVkeHUh?=
CAMA-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jN[mlEPTB;Mke4MlI4QSEQvF2=	NFPvZmFUSU6JRWK=
NCI-H1792	NH64NI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXxTWM2OD1{N{muNVg4KM7:TR?=	MlPNV2FPT0WU
UACC-893	NVnrWFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jsRWlEPTB;MkiwMlU1KM7:TR?=	Ml\3V2FPT0WU
TGW	NGXWS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJ6Mz6wOVgh\|ryP	MnnQV2FPT0WU
SH-4	MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37RR2lEPTB;MkizMlEzOyEQvF2=	MUPTRW5ITVJ?
NCI-H2009	NGKwOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrXWGNPUUN3ME2yPFMvQTV\|IN88US=>	MX7TRW5ITVJ?
T84	M4XxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJ6ND62OlUh\|ryP	MWHTRW5ITVJ?
EW-7	M4TieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHXTWM2OD1{OEWuNlMzKM7:TR?=	NVG1SodDW0GQR1XS
NCI-H1882	NHzHc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLWd45JUUN3ME2yPFYvODN3IN88US=>	MWjTRW5ITVJ?
GMS-10	NXKze4R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zER2lEPTB;Mki3MlE5OyEQvF2=	M4PZV3NCVkeHUh?=
HC-1	NEnTfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETWfmdKSzVyPUK5NE43ODJizszN	MkjKV2FPT0WU
ABC-1	NFj3OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJ7MT6wOlkh\|ryP	M{fjS3NCVkeHUh?=
HuP-T3	M1HzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnsc4I3UUN3ME2yPVIvOTR4IN88US=>	M{DtPXNCVkeHUh?=
HT-1197	NGrrXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJ7Mj64O\|kh\|ryP	NGK1VG9USU6JRWK=
SHP-77	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULTd453UUN3ME2yPVUvPTl5IN88US=>	MXjTRW5ITVJ?
NCI-H524	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\uXmRKSzVyPUK5OU44PjlizszN	NFjmVXhUSU6JRWK=
SW626	M{jtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEOwbVlKSzVyPUK5Ok4yOTVizszN	MVnTRW5ITVJ?
NCI-H2347	NF7oeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DnRWlEPTB;Mkm2MlQzPSEQvF2=	NUfXVmlXW0GQR1XS
U251	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDxb\|QxUUN3ME2yPVgvPDN6IN88US=>	M3LxWnNCVkeHUh?=
RL95-2	NInFU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfYNFlRUUN3ME2zNFAvOjR5IN88US=>	NVTtOm5OW0GQR1XS
C2BBe1	NX3yfFRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TpUGlEPTB;M{CwMlY6OSEQvF2=	NGfvfmtUSU6JRWK=
HLE	NYL6e\|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[3VWlEPTB;M{CxMlgyQCEQvF2=	NUTSNpJpW0GQR1XS
COLO-680N	M3vhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPqTWM2OD1\|MEKuPFk{KM7:TR?=	M{D0fHNCVkeHUh?=
PLC-PRF-5	MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\O[FZIUUN3ME2zNFQvQTB5IN88US=>	M37rXnNCVkeHUh?=
SCC-15	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfvTWM2OD1\|ME[uNFE4KM7:TR?=	MUnTRW5ITVJ?
ECC12	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXOzdW9KUUN3ME2zNVAvOjV2IN88US=>	MlTlV2FPT0WU
A388	NX70VIlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PacGlEPTB;M{GyMlAzOiEQvF2=	NHXmfVVUSU6JRWK=
ES1	NUfVfYc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTNzMj6xPFkh\|ryP	NVnuNmxXW0GQR1XS
J-RT3-T3-5	NYTpN41wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjkdHpKSzVyPUOxN{42OjFizszN	M4[3RXNCVkeHUh?=
SNU-475	M{Xsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDQbGhKUUN3ME2zNVQvODlzIN88US=>	NWX0OlV6W0GQR1XS
647-V	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfZb3pKSzVyPUOxOE43PzNizszN	MV\TRW5ITVJ?
IMR-5	NWGzSXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\oW5BiUUN3ME2zNVUvOzhizszN	Mn;2V2FPT0WU
EW-24	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLwb2ZKSzVyPUOyNE4xPyEQvF2=	M124UHNCVkeHUh?=
CAL-51	NGXYW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S5VmlEPTB;M{KxMlQxOyEQvF2=	NGTSTG1USU6JRWK=
HD-MY-Z	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHwS\|dVUUN3ME2zNlEvPDB7IN88US=>	Mn\ZV2FPT0WU
EW-13	NITLdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHzUHlKSzVyPUOyNk41OjRizszN	M1Ox[3NCVkeHUh?=
SK-N-FI	NIS5eFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFX3NFJKSzVyPUOyNk41PTJizszN	NUjIZoc4W0GQR1XS
BHY	MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnPSnp{UUN3ME2zNlMvOTd3IN88US=>	NXnYXWhDW0GQR1XS
OCUB-M	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7SUG1HUUN3ME2zNlMvPDN2IN88US=>	Ml3BV2FPT0WU
HCC1954	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;5dGlEPTB;M{KzMlU5OiEQvF2=	NXm2RoVrW0GQR1XS
SK-MEL-24	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljrTWM2OD1\|MkSuNVEyKM7:TR?=	MV;TRW5ITVJ?
NTERA-S-cl-D1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTN{Nj60PFkh\|ryP	NGTHfW5USU6JRWK=
SK-MEL-30	MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml6yTWM2OD1\|Mk[uO\|M5KM7:TR?=	MkHrV2FPT0WU
LS-123	NUTlfZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17FOmlEPTB;M{K4MlE3PCEQvF2=	MUDTRW5ITVJ?
SF268	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPP[pdKSzVyPUOzNE4zPjVizszN	MnfIV2FPT0WU
BT-474	NYDD[ZJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHnTWM2OD1\|M{KuOFE5KM7:TR?=	M{fqNXNCVkeHUh?=
NCI-H1522	M3zFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHYOWJKSzVyPUOzOE4{OzlizszN	NXrv[pByW0GQR1XS
LC-2-ad	NE\WSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fNbWlEPTB;M{O2MlU6OSEQvF2=	MmPpV2FPT0WU
LAN-6	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvHb\|NKSzVyPUOzOk46PzdizszN	NUHZTIJMW0GQR1XS
ARH-77	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLqT5B5UUN3ME2zN\|cvOzJizszN	NFXVTYVUSU6JRWK=
HuO9	NYfM[pQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\l[5FVUUN3ME2zN\|cvPDdizszN	NFrFSm9USU6JRWK=
MLMA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrIS2FKSzVyPUOzPE4yPTVizszN	MV;TRW5ITVJ?
Raji	NVvId5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfSN4VXUUN3ME2zN\|gvOzhizszN	M1npenNCVkeHUh?=
GT3TKB	NVXEZ4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTN\|OD60NVIh\|ryP	M{Xsc3NCVkeHUh?=
NCI-H441	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVmwc\|FwUUN3ME2zOFEvPDF6IN88US=>	M4\JTXNCVkeHUh?=
NCI-H2030	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;LdFBxUUN3ME2zOFEvPjB7IN88US=>	Ml;rV2FPT0WU
VM-CUB-1	M{fifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jiOGlEPTB;M{SyMlY{PiEQvF2=	NFiyRmhUSU6JRWK=
KP-4	NHnoeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTN2Mz63N\|Mh\|ryP	MUjTRW5ITVJ?
PF-382	M1jtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jSS2lEPTB;M{S0MlQzOiEQvF2=	M2XXT3NCVkeHUh?=
NB13	NGfnSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTN2NT61PEDPxE1?	NUfQdYc2W0GQR1XS
D-502MG	NVKzRpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIq2SoZKSzVyPUO0OU45OTJizszN	NUnQRmd3W0GQR1XS
CAL-54	NW\DdXZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTN2NT64O\|kh\|ryP	MX\TRW5ITVJ?
DOHH-2	M{PoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjiNIJPUUN3ME2zOFYvPjVizszN	NUL5WWNIW0GQR1XS
SK-PN-DW	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILNUmFKSzVyPUO0O{41OjZizszN	NIfSN2pUSU6JRWK=
NCI-H720	M3;odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfL[Zk5UUN3ME2zOFkvQDR4IN88US=>	NV\DfIR1W0GQR1XS
SW1990	NX\4PIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrzRpNKSzVyPUO1NU4zQCEQvF2=	MYnTRW5ITVJ?
NCI-H2196	NF3k[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTN3Mj62NlQh\|ryP	NVL3e\|Y6W0GQR1XS
P30-OHK	NHTLOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGewVGpKSzVyPUO1N{4xPjNizszN	NX\idm1qW0GQR1XS
NCI-H358	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MniwTWM2OD1\|NUWuN\|U3KM7:TR?=	MUTTRW5ITVJ?
CW-2	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF76fIRKSzVyPUO1Ok42OjlizszN	MYrTRW5ITVJ?
COLO-678	M1LZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTN3Nz64OlMh\|ryP	MlvoV2FPT0WU
NCI-H2126	NF;OVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjEeodKSzVyPUO1PE42OjFizszN	MUTTRW5ITVJ?
DMS-53	NX7t[XBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zKV2lEPTB;M{W4MlcyOSEQvF2=	NWThOGhQW0GQR1XS
NCI-H1838	M4fMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HrNmlEPTB;M{W5Mlk5PyEQvF2=	M2TrcnNCVkeHUh?=
SJSA-1	NUfYTGhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTN4MD65N\|kh\|ryP	NUPWepE1W0GQR1XS
ChaGo-K-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T0OWlEPTB;M{[zMlkzPCEQvF2=	NVi0UHJCW0GQR1XS
IST-SL2	NXzHUGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTN5Mj65NlYh\|ryP	MkPpV2FPT0WU
U-266	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEmzcXJKSzVyPUO3N{4yOzJizszN	M3XWOXNCVkeHUh?=
P31-FUJ	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTN5Nj65OlQh\|ryP	NXzOfINEW0GQR1XS
HCC2157	M1H6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEP1bZVKSzVyPUO3PE4yPjFizszN	MlLrV2FPT0WU
COR-L88	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEG5XG1KSzVyPUO4N{43PzdizszN	NUXhOXVbW0GQR1XS
NCI-H596	M1;EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zJT2lEPTB;M{i1MlM1KM7:TR?=	NFr6R5BUSU6JRWK=
GOTO	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3TNpRKSzVyPUO5NE43PDFizszN	M{PSTnNCVkeHUh?=
NCI-H719	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTN7MT64PVMh\|ryP	NUfDeYxDW0GQR1XS
MN-60	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfpdoxKSzVyPUO5N{46PDhizszN	MknqV2FPT0WU
IST-SL1	M4mzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTxUm9KSzVyPUO5OE41ODZizszN	NF3pbHRUSU6JRWK=
TE-6	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHZTWM2OD1\|OUeuNlU1KM7:TR?=	MorBV2FPT0WU
SW962	M3vnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmW0TWM2OD1\|OUiuOlkh\|ryP	M4fUTXNCVkeHUh?=
FADU	M2XobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnpbHlKSzVyPUSwN{4xQDNizszN	NVT2[JFFW0GQR1XS
ECC4	NYjhdmU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfoSpdKSzVyPUSwPE41PThizszN	MWXTRW5ITVJ?
MES-SA	NG\STFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPpPWVKSzVyPUSwPU46QCEQvF2=	M4DFW3NCVkeHUh?=
NCI-H716	NFjISm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDneWxsUUN3ME20NVAvODd3IN88US=>	M3\jW3NCVkeHUh?=
GR-ST	NGXOWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHVTWM2OD12MUCuOFk4KM7:TR?=	MV7TRW5ITVJ?
KY821	M3XkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvuTppKSzVyPUSxOE4xQDZizszN	MV\TRW5ITVJ?
NCI-H2141	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnnN29KSzVyPUSyOE4{QDhizszN	NXGzN4dGW0GQR1XS
MDA-MB-134-VI	NWfSW2dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\ROHVyUUN3ME20N\|EvODN\|IN88US=>	MnixV2FPT0WU
RH-1	NInUUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXn[ZRKSzVyPUSzOU4xQSEQvF2=	M1vPZ3NCVkeHUh?=
AM-38	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vSPGlEPTB;NEO4MlU1KM7:TR?=	M4\JO3NCVkeHUh?=
BL-70	M4Xib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvqbGFUUUN3ME20N\|kvPDJ7IN88US=>	NWr6RmNSW0GQR1XS
COLO-684	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPiZYVKSzVyPUS0PE45QDhizszN	NVi3OXdQW0GQR1XS
DMS-79	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTR2OT62PEDPxE1?	MlPTV2FPT0WU
EW-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojUTWM2OD12NUKuPFg5KM7:TR?=	NU\sV5BLW0GQR1XS
MS-1	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3OZmRKSzVyPUS1OE4{QDVizszN	M3rIOHNCVkeHUh?=
A4-Fuk	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTR3ND61NFch\|ryP	NIXCXZhUSU6JRWK=
TALL-1	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfLTWM2OD12NUWuNlk4KM7:TR?=	M{\EbnNCVkeHUh?=
SCLC-21H	M1TuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXQN5RKSzVyPUS1OU43QTlizszN	MWfTRW5ITVJ?
KMS-12-PE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\2dnFrUUN3ME20OVYvQDJ{IN88US=>	NWPue\|l5W0GQR1XS
TE-441-T	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTR3Nz6xPFYh\|ryP	MoTZV2FPT0WU
A3-KAW	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXJemZVUUN3ME20OlAvQDRzIN88US=>	NGrr[Y1USU6JRWK=
NCI-H1092	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK3TWM2OD12NkOuPVQ{KM7:TR?=	NFjh[WpUSU6JRWK=
COR-L279	M4fpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrveopYUUN3ME20OlQvQDR5IN88US=>	NV;IcZFxW0GQR1XS
NCI-SNU-5	NHfSO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3sTWM2OD12N{KuNlgh\|ryP	MVjTRW5ITVJ?
JAR	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW0[HVEUUN3ME20O\|QvPzh6IN88US=>	NHvS[G9USU6JRWK=
NCI-H446	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEH4U49KSzVyPUS3O{4xQCEQvF2=	NXXk[WFmW0GQR1XS
HDLM-2	NELmUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXrcYFGUUN3ME20PFAvQDZ7IN88US=>	MorJV2FPT0WU
D-283MED	NFHIXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDsTWM2OD12OEiuPVI1KM7:TR?=	NX;Gb4lrW0GQR1XS
NCI-H1395	M3XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo[wTWM2OD12OEmuNFA1KM7:TR?=	MXfTRW5ITVJ?
RPMI-6666	M3HqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCwTWM2OD12OUGuN\|k5KM7:TR?=	M3nLeXNCVkeHUh?=
CPC-N	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETsPWJKSzVyPUWwNk4xPjNizszN	MVvTRW5ITVJ?
EC-GI-10	M4X1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1i3bGlEPTB;NUCyMlE3QSEQvF2=	MV7TRW5ITVJ?
CA46	M{fNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV2wVINNUUN3ME21NFQvPDB5IN88US=>	Mn\kV2FPT0WU
EHEB	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;UTWM2OD13MEeuNlA5KM7:TR?=	NWTVcZJiW0GQR1XS
RPMI-8402	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XVZ2lEPTB;NUGwMlAzOSEQvF2=	NGrmXFJUSU6JRWK=
DU-4475	NVjCfGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nENGlEPTB;NUGxMlExOSEQvF2=	NYflOlkyW0GQR1XS
P12-ICHIKAWA	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXlfYFPUUN3ME21NVEvPDF4IN88US=>	NWrsb5Y3W0GQR1XS
NCI-H1694	NV3Fd21wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;ITHBxUUN3ME21NVIvPDN7IN88US=>	NXPKRYtlW0GQR1XS
NCI-H2171	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4O1Z2lEPTB;NUGyMlcxPSEQvF2=	MVPTRW5ITVJ?
Mo-T	M13jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnNeJZKSzVyPUWxOU4yOTZizszN	NHPLN5NUSU6JRWK=
HL-60	M2L0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjLTWM2OD13MkKuPVI1KM7:TR?=	NY\EcI53W0GQR1XS
NCI-H1436	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M172VWlEPTB;NUKzMlA3PCEQvF2=	MXHTRW5ITVJ?
NCI-H510A	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPy[m1KSzVyPUWyOE43QTZizszN	NV7PSXJIW0GQR1XS
NCI-H2081	M1fMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\rSWlEPTB;NUK1MlUyOyEQvF2=	NEPER3ZUSU6JRWK=
NB5	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\zNIE5UUN3ME21NlYvPDNizszN	MYjTRW5ITVJ?
NCI-H2227	NWrqXng6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzoOI9KSzVyPUWzNE4zPTRizszN	MnvqV2FPT0WU
HSC-4	M2[4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTV\|OT6yPVMh\|ryP	NIPBdldUSU6JRWK=
RL	NFziZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTV2Mj60OFIh\|ryP	M{[yfnNCVkeHUh?=
EVSA-T	M2P5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\0TWM2OD13NEOuOlg1KM7:TR?=	NGD3NopUSU6JRWK=
NCI-H889	NHPOdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILhdZFKSzVyPUW0O{4zOyEQvF2=	M{PXNHNCVkeHUh?=
COLO-320-HSR	M1LD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvEfJdmUUN3ME21OVEvOzVizszN	Ml;BV2FPT0WU
EW-11	MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTV3Mj6zPVkh\|ryP	M{nwR3NCVkeHUh?=
UACC-812	NH\Jd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jwTGlEPTB;NUW5MlM6OSEQvF2=	NF3nVoRUSU6JRWK=
CAL-148	NVfu[nl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jKVGlEPTB;NU[1MlA5QSEQvF2=	NHf6XZdUSU6JRWK=
K052	NGm2NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWX3dHByUUN3ME21O\|kvOjF\|IN88US=>	MYLTRW5ITVJ?
L-428	NIrKW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTZyMD62O\|Eh\|ryP	MVnTRW5ITVJ?
LP-1	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;aU4hxUUN3ME22NFMvPTh5IN88US=>	NV3DVYp2W0GQR1XS
ML-2	NF[zb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH30cHpKSzVyPU[wOk42PzlizszN	MYXTRW5ITVJ?
KARPAS-45	M4fKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTRTHJuUUN3ME22NVgvOjJzIN88US=>	NIrM[pRUSU6JRWK=
HT	NYX4XXczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LP[2lEPTB;NkKyMlc5PSEQvF2=	M4fnWnNCVkeHUh?=
NCI-H226	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTZ{OD6zOVMh\|ryP	M3jr[nNCVkeHUh?=
L-363	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlP1TWM2OD14NEiuNFY1KM7:TR?=	M2PBXXNCVkeHUh?=
IM-9	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzwV\|dKSzVyPU[1NU42PDFizszN	MmXuV2FPT0WU
TUR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PkNWlEPTB;NkexMlMzOiEQvF2=	MoXZV2FPT0WU
NCI-SNU-16	NV;nRpo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTZ6MD60OlIh\|ryP	NX;OTZBMW0GQR1XS
NCI-SNU-1	Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTZ7MD6xO\|Ih\|ryP	MnLEV2FPT0WU
U-87-MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{ftO2lEPTB;Nkm0MlU5PSEQvF2=	M4nWeHNCVkeHUh?=
KM-H2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17Kc2lEPTB;Nkm5MlA2QSEQvF2=	NUXjNlBTW0GQR1XS
DEL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIm4ZW1KSzVyPUewNE45OzhizszN	MWPTRW5ITVJ?
KARPAS-422	NIHsN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;oTWM2OD15OEmuN\|E2KM7:TR?=	MkK0V2FPT0WU
BC-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j1dWlEPTB;OEC1MlIxOyEQvF2=	MXHTRW5ITVJ?
NCI-H1155	NIe1UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[0TWM2OD16MUiuNFU6KM7:TR?=	NUPX[29oW0GQR1XS
NCI-H1581	NVrFW3psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIP5U4ZKSzVyPUmwNE4zOzFizszN	NIfhcGVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / CD31 / VE-Cadherin / α-SMA / vimentin; PubMed: 30709379 J Exp Clin Cancer Res NCI-H460 cells were co-cultured with HUVECs in a 3D culture system, and then treated with 1 μM CHIR-99021, 10 μM or 20 μM Cisplatin, or a combination of both, for 24 h. Cells were harvested and immunoblotted with anti-cleaved PARP, anti-CD31, anti-VE-cadherin, anti-α-SMA, anti-vimentin, and anti-β-actin antibodies. CTNNB1; PubMed: 23993102 Cell Treatment with the GSK3β inhibitor CHIR-99021 led to increased levels of β-catenin in RKO and HT29 (non-mutant) cells. β-catenin; PubMed: 24165128 J Biol Chem HeLa cells were treated with 5 μm CHIR-99021 for the indicated times. The samples were analyzed by Western blot.	30709379 23993102 24165128
Growth inhibition assay	Cell viability; PubMed: 22039301 J Immunol HMC-1.2 cells were cultured in the absence or presence of GSK3β inhibitor (CHIR 99021, 3–30 µM) and viability cell count was assessed by trypan blue dye exclusion after 24 h, 48 h or 72 h. All data are presented as the mean ± SEM of three independent experiments conducted in triplicate. p < 0.05, p < 0.001* p < 0.0001*** vs vehicle treated control cells.	22039301
Immunofluorescence	SOX10 / EdU; PubMed: 28174705 Cell Mol Gastroenterol Hepatol Incorporation of EdU (white arrowheads) into SOX10+ ENS (enteric nervous system) cells with and without CHIR-99021. Oct3/4; PubMed: 24779365 BMC Res Notes Fluorescence micrographs showing the protein expression of Brachyury/Oct3/4 after a three day differentiation of ES-D3 cells with BIO (0.5 μM), SB-216763 (5 μM), CHIR-99021 (5 μM), or CHIR-98014 (1 μM). Nuclei were counterstained with DAPI (blue). The merge is shown in yellow. Original magnification 400x. Scale bar = 50 μm.	28174705 24779365

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge. ^[1] Administration of CHIR-99021 significantly augments hematopoietic repopulation in recipient mice transplanted with mouse or human hematopoietic stem cells (HSCs), suggesting that GSK-3 is a specific modulator of HSC activity. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cell-free kinase assays: Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing 27 nM GSK-3α or 29 nM GSK-3β, and 0.5 μM biotin-CREB peptide substrate. Various concentrations of CHIR-99021 are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 minutes, and counted in a scintillation counter. All steps are performed at room temperature.
Cell Research: ^[3]	- Collapse Cell lines: INS-1E Concentrations: Dissolved in DMSO, final concentrations ~ 20 μM Incubation Time: 1, or 4 days Method: Cells are maintained for 24 hours in starvation medium (culture medium with only 5 mM glucose, 1% fetal calf serum). Then cells are exposed to various concentrations of CHIR-99021 for 1, or 4 days. Cell number is measured by staining of cellular DNA with CyQuant dye, which becomes fluorescent when bound to DNA. Fluorescence is measured after 30 minutes of incubation using the FLUOstar Optima reader. Cell replication is determined by BrdUrd incorporation. BrdUrd labeling solution is added to the medium for the last 4 hours before the cells are fixed using FixDenat solution and incubated with monoclonal anti-BrdUrd-POD antibodies. After substrate solution is added to each well, the light emission is measured in a microplate luminometer using the Analyst HT detection system. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female db/db mice or male ZDF rats with type 2 diabetes Dosages: ~48 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL (185.33 mM)
	Water	Insoluble
	Ethanol	'2 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	24mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Molecular Weight	501.8
Formula	C₂₂H₁₈Cl₂N_8.HCl
CAS No.	1797989-42-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I recently purchased CHIR 99021 to inject mice intraperitoneally. The data sheet says using 10% captisol for in vivo use. Is it for IP injection? Or do you have other solutions to suggest to use for in vivo IP injection of CHIR 99021?
Answer:
The formulation of 15% Captisol is for oral gavage, and S2924 CHIR-99021 (CT99021) HCl in it is a suspension. S2924 CHIR-99021 (CT99021) HCl can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 24mg/ml as a clear solution for IP injection.
Question 2:
How about the half-life of this compound? If it is necessary for daily treatment when the compound is used in long-term experiment?
Answer:
Please change the culture medium each day to add the new comound in it if the duration is more than 72h.
Question 3:
What is the difference between S2924 and S1263? Which one is better for differentiation?
Answer:
S1263 is the free base format of Chir-99021, while S2924 is the HCl salt format. They have the same biological activity but are slightly different in solubility.

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Selective GSK-3 Inhibitor

TWS119 : GSK-3β-selective, IC50 of 30 nM.
Most Potent GSK-3 Inhibitor

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
GSK-3 Inhibitor in Clinical Trial

Tideglusib : Phase II for Alzheimer's disease.
Newest GSK-3 Inhibitor

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

Related GSK-3 Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 (NP 01139) is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology. GSK-3β inhibition triggers autophagy.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.
Tideglusib

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
BIO

BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

Features:The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
AR-A014418

AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.
IM-12

IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl